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Abstract 
Improving cancer survival in the UK is one of the leading items on the agenda 
of the government. Survival from gastrointestinal cancer is yet to come into 
line with Europe. In 2000 the department of health (DoH) introduced 
guidelines for referral of patients with suspected cancer. Iron deficiency 
anaemia (IDA) is one of the criteria for urgent referral for suspected cancer of 
the upper and lower gastrointestinal tract. The British Society of 
Gastroenterology (BSG) produced guidance on investigating patients with 
IDA to ensure identification of sources of occult blood from the GI tract. 
However due to a lack of clear guidance on how to streamline patients into 
upper or lower GI investigation pathways has resulted in significant delays. 
Furthermore there is evidence that there is significant delay in diagnosing 
proximal colon cancers in patients presenting with anaemia due to time spent 
in the investigation loop.  
A literature review was conducted and this confirms that in patients above the 
age of 45 with unexplained IDA an upper GI cause is present in 40-60% of 
patients. Lower GI blood loss accounts for 26 to 31% of causes of anaemia. 
Colon cancer is the commonest cause with 11% on average for all causes of 
anaemia.  
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We also studied the incidence and profiles of anaemia in a cohort of patients 
with common GI malignancies.  The incidence of anaemia that met the DOH 
and BSG guidance was 22% and 25% respectively.  
We identified a potential for blood profiling to help differentiate upper and 
lower GI malignancies. Proximal colon cancer presented with a higher 
proportion of patients with anaemia and lower MCV, MCH, MCHC and a 
higher RDW as compared to upper GI cancers. We also identified a need to 
reduce the haemoglobin threshold for referral of any patient over the age of 
45 with unexplained anaemia.  
We conducted a prospective study assessing symptoms and blood profiles of 
patients referred with anaemia to a dedicated clinic. Using these profiles a 
scoring tool to predict likelihood of site of cause of anaemia was generated. 
We confirmed the poor sensitivities and specificities of symptoms for 
conditions of the GI tract in the presence of anaemia. However symptom 
combinations improved the sensitivity and specificity for identification of 
patients at risk of having serious conditions causing anaemia. 
The scoring tool combined symptoms and blood profiles to aid in 
streamlining patients to the appropriate investigation. The tool generated a 
probability of having a serious condition causing anaemia in the upper or 
lower GI tracts. The scoring tool had a high discriminatory power with a 
sensitivity and specificity to GI causes of anaemia better than the current 
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guidelines. A clinical pathway is proposed where the scoring tool is used to 
aid in streamlining investigation.   
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Chapter 1 
Background and review of literature 
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Introduction 
In response to the findings of the EUROCARE[2, 3] study report on survival of 
cancer, the Department of Health (DoH) and the National Health Service 
(NHS) introduced initiatives and cancer care plans to improve survival from 
cancer[4]. The target was by 2010 to reduce mortality of all cancers in 
patients aged under 75 by 20%  in comparison with a 1995-97 baseline[5].  
Early referral has a role to play in the improvement of care for people with 
cancer, and in some cancers early referral may improve survival rates[5]. 
Primary health care has particular responsibility for the early detection of 
cancer and the initiation of speedy referral to specialist services. A recent 
report by the National Audit Office (2004)[6] on cancer services in England 
observed that patients in England tend to have more advanced cancer at the 
time of diagnosis than some other countries, particularly in breast and bowel 
cancer. Delay in diagnosis at primary care could be explained by the failure 
of some patients to seek help quickly, and by the difficulties general 
practitioners can face in identifying people with cancer, hence delayed 
referral. However once the patient is referred further delay could occur 
awaiting appointment to secondary care, investigation or treatment [7]. 
The DoH report in 2002, categorized bowel cancer as a major health problem 
[7]. Bowel cancer 5 year survival is less than 40%. It has considerable burden 
on the NHS, and individuals suffering with it. 
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Table 1.1 demonstrates the incidence of selected cancers in UK. 
 
Table 1.1: Newly diagnosed cancers in the UK 2006-2008: selected sites. 
Cancer  
Gender 
Total New Cases 
p.a. 
No p.a. per 
100,000 
population(95%CI) 
Upper GI 
Oesophagus 
M 5285 14.5(14.3-14.8) 
F 2778 5.6(5.5-5.7) 
Stomach 
M 5019 13.2(13.0-13.4) 
F 2777 5.4(5.3-5.5) 
Pancreas 
M 3916 10.6(10.4-10.8) 
F 4094 8.3(8.2-8.5) 
Lower GI Colorectal 
M 21070 56.7(56.3-57.1) 
F 17211 36.3(36.0-36.6) 
 
 
Table 1.2: Total deaths from cancer males and females, all ages, UK 2006-2008.  
 
Cancer group Male Female 
  
Colorectal cancers  8,489  7,342 
Oesophagus 4,900  2,559 
Stomach 3,240  1,989 
Adapted from Office for National Statistics. Death from cancer: selected sites 
by gender,2006-2008[8].  
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DOH guidelines for referral of patient with suspected colon cancer.  
Colorectal cancer is the 3rd cause of cancer related deaths in both men and 
women[8]. The mortality has improved since 1995 with a reduction from 
28.2 to 24.9 deaths per 100,000 in males in 2003 and from 18 to 14.5 per 
100 000 women in 2003 (Table 1.3)[9].  
 
Table1.3. Death rates from selected cancers: by sex in the United Kingdom. 
Rates per 100,000 population 
 
  
Males Females 
Colon 
Rectosigmoid 
and Anus 
 Colon 
Rectosigmoid 
and Anus 
1995 18.2 10 1995 13.1 4.9 
1996 17.5 9.9 1996 12.6 4.9 
1997 17.6 9.3 1997 12.2 4.8 
1998 16.9 9.5 1998 11.7 4.7 
1999 16.1 9 1999 11.6 4.6 
2000 15.8 8.9 2000 10.7 4.5 
2001 15.6 8.9 2001 10.3 4.5 
2002 15.1 9.1 2002 10.4 4.4 
2003 15.7 9.2 2003 9.9 4.6 
 
Due to the poor survival compared with Europe and the USA, major reforms 
in screening and referral of symptomatic patients have been introduced.  
There are about 30,000 cases of colorectal cancer per year in England and 
Wales (3). 99% are aged above 40 years.  
To assist primary healthcare professionals identify people with suspected 
cancer as early as possible, the Department of Health issued guidelines on 
the topic in 2000[10]. The two week rule and referral guidelines were 
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introduced to facilitate recognition and streamlining of patients with high 
risk of cancer. The primary aim was to identify 90% of patients with bowel 
cancer through this new system [4].  
The guidelines are based on high risk symptoms and signs of any abdominal 
masses and anaemia. 
It is recommended that WHEN OCCURRING FOR THE FIRST TIME these 
symptom and sign combinations should be used to identify patients for 
urgent referral under the two week standard [4]. 
• Rectal bleeding WITH a change in bowel habit to looser stools and/or 
increased frequency of defecation persistent for 6 weeks. all ages; 
• A definite palpable right-sided abdominal mass, all ages; 
• A definite palpable rectal (not pelvic) mass, all ages; 
• Rectal bleeding persistently WITHOUT anal symptoms if over 60 yrs; 
• Change of bowel habit to looser stools and/or increased frequency 
of defecation, WITHOUT rectal bleeding and persistent for six weeks, 
over 60 yrs; 
• Iron deficiency anaemia WITHOUT an obvious cause 
(Hb < 11 g/dl in men or < 10 g/dl in postmenopausal women). 
Under the umbrella of NICE, these guidelines where further revisited by an 
advisory group in 2002 and report published by the Department of Health 
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[5]. NICE also analysed the evidence and endorsed the guidelines with an aim 
for a second consultation [5].  
The evidence for the referral guidelines is based on predictive values derived 
in hospital studies and on the common modes of presentation of established 
bowel cancer.  
The guidelines aimed to prioritise those patients most likely to have cancer 
so that with existing resources, most will be seen in outpatients within two 
weeks of referral. The aim is that as the resources for investigation are 
improved, the criteria for access to the fast-track clinics can be increased and 
age thresholds lowered so that more patients with lower risk symptoms can 
be included[5]. 
The high risk criteria for referral are based on symptoms and signs that are 
commonly associated with colon cancer[7]. 
The incidence of primary bowel symptoms varies with site [7, 11, 12].  The 
mode of presentation for the left and right colon demonstrates clearly 
separate patterns (Table 1.4). Proximal colon cancer (proximal to sigmoid 
colon) commonly presents with one of the three cardinal factors: intestinal 
obstruction, anaemia or an abdominal mass [11, 13, 14].  Nearly a third 
attends as an emergency [15]. Primary symptoms have been identified in 
patients with proximal cancer but usually in the presence of the main 
cardinal features. Primary symptoms exist on their own in only 5%. In 
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contrast, tumours situated in the descending colon, sigmoid colon or rectum, 
usually present with distinct primary symptoms [11, 16-18]. 
 
Table 1.4: Prevalence of symptoms of colorectal cancer grouped by site [ 7]. 
Distal colon cancer Proximal colon cancer 
Rectal bleeding and a change 
in bowel habit 
55-65% Anaemia with 
            Primary symptoms 
No primary symptoms  
Abdominal mass 
54% 
48% 
52% 
43% 
Change in bowel habits alone 20-25% Primary symptoms with 
Anaemia 
Abdominal mass 
Emergency surgery 
72% 
37% 
44% 
49% 
Rectal bleeding alone 15-20% Emergency surgery 34% 
  Primary symptoms on their own 5% 
Primary symptoms: Change in bowel habits, Rectal bleeding, Abdominal pain  
 
The DoH referral guidelines have been widely disseminated and 
implemented. However, accuracy and efficacy remains a concern [19-24]. 
The poor specificity of the guidelines [24] resulted in an increase number of 
referrals without increasing the yield of cancer detection. Failure to 
implement the guidelines accurately has also resulted in further reduction of 
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cancer detection with a significant number of cancers presenting through 
routine routes [21, 25]. 
Although cancer survival is dependent on several factors, as yet there is no 
evidence to suggest that introduction of current referral guidelines have 
improved on survival[26]. 
Hence, improving the specificity and the sensitivity of a risk assessment tool 
will enable better targeting for assessment of high risk patients to improve 
delay in diagnosis and shift stage of cancer. 
Selvachandran et al [16] improved the sensitivity and specificity of colorectal 
symptoms and symptom complexes to detect colon cancer by allowing for a 
score to be generated to stratify risk. This has proven effective in identifying 
early distal colorectal cancer[27]. The difficulty in achieving an improvement 
in proximal colorectal cancer detection perhaps lies in the fact that the 
cardinal symptom of presentation; iron deficiency anaemia (IDA), is non-
specific.  
However, as  IDA provides a portal for detecting proximal colorectal and 
upper GI malignancies, further emphasis on its value as a high risk criterion is 
demonstrated by its incorporation in the referral guidelines for suspected 
bowel and upper GI malignancies [10].  
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Guidelines for referral of patients with suspected oesophageal or gastric 
cancer. 
In 1997 approx 6,000 oesophageal and 10,000 gastric cancer cases were 
diagnosed in England and Wales. The incidence of stomach cancer is 
decreasing, whereas the incidence of oesophageal cancer is increasing. 
Tumours at the junction between the stomach and oesophagus are 
increasing particularly rapidly with 99% of cases occurring in patients over 40 
years and 90% of gastric cancers occurring in patients  over 55 years. [5, 10] 
In an attempt to aid identifying patients at high risk of having 
oesophagogastric cancer the DoH introduced  guidance in 2000[10]. This was 
later reviewed and endorsed by NICE [5].  
The Department of health guidance on referral with suspected upper GI 
cancer: 
Referral with in the 2 week rule should be undertaken in any patients with -  
• Dysphagia – food sticking on swallowing (any age); 
• Dyspepsia at any age combined with one or more of the following ‘alarm’ 
symptoms: 
- weight loss 
- proven anaemia 
- vomiting 
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• Dyspepsia in a patient aged 55 years or more with at least one of the 
following ‘high risk’ features: 
- Onset of dyspepsia for less than one year;  
- Continuous symptoms since onset. 
• Dyspepsia combined with at least one of the following known risk factors: 
- Family history of upper GI cancer in more than 2 first degree relatives 
- Barrett’s oesophagus 
- Pernicious anaemia 
- Peptic ulcer surgery over 20 years ago 
- Known dysplasia, atrophic gastritis, intestinal metaplasia 
• Jaundice 
• Upper abdominal mass 
 
As upper GI cancers are relatively uncommon in primary care and dyspeptic 
symptoms very common, the chance of a dyspeptic patient under the age of 
55 having gastric cancer is extremely low[28, 29]. Dyspepsia is very common 
in the general population [30] and a poor predictor of cancer[31-33]. 
Unfortunately the symptoms yielding a higher predictive power for upper GI 
cancer such as dysphagia, weight loss and anaemia are associated with 
advanced stage[34]. 
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However the combination of upper GI symptoms has been shown to provide 
some degree of accuracy in predicting upper GI cancer [31]. 
In a study by Irving et al[35]  the introduction of referral guidelines has 
improved the delay from first general practitioner consultation to 
endoscopy, however the stage of cancer did not differ from before 
introduction of the guidelines.  
Anaemia in the presence of dyspeptic symptoms is also reported to increase 
the risk of presence of upper GI cancer [5]. Anaemia is a more common 
presentation in gastric cancer (22%) than in oesophageal cancer (5.5%)[36]. 
Nevertheless, as anaemia is a mode of presentation of both upper and lower 
GI cancers then the investigation of patients over the age of 45 presenting 
with unexplained anaemia needs to be targeted to rule out cancer as a 
priority.   
 
Iron deficiency anaemia and investigation in secondary care. 
IDA occurs in 2–5% of adult men and post-menopausal women in the 
developed world and is a common cause of referral to a gastroenterology 
clinic (4–13% of referrals)[37]. While menstrual blood loss is the commonest 
cause of IDA in pre-menopausal women, blood loss from the gastrointestinal 
(GI) tract is the commonest cause in adult men and post-menopausal women 
[38-41]. Asymptomatic colonic and gastric carcinoma may present with IDA 
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and exclusion of these conditions is of prime concern. The management of 
IDA is often suboptimal with most patients being incompletely investigated, 
if at all [42]. 
The British Society of Gastroenterology (BSG) published its guidelines for the 
investigation of IDA in 2000[1].  Although guidelines where based on 
relatively weak evidence they have been accepted widely [1]. It has been 
reported that since these guidelines have been published there has been an 
increase in the identification of GI malignancies [43-46]. However, benefit in 
detecting early cancer remains to be demonstrated.  
Several issues have been highlighted by the BSG, DoH and NICE guidelines. 
These include the high incidence of IDA and its effect on resources; the high 
threshold of anaemia which directs investigation of IDA; and the value of 
investigating those with non-iron deficiency anaemia. These issues are yet to 
be clarified [1, 5, 10]. Although the DoH guidelines stipulate early referral of 
patients with IDA to secondary care, there is no clear guidance on how 
secondary care should manage this cohort. The BSG guidelines (Figure 1.1) 
have not clearly identified criteria for investigation selection following 
referral to secondary care. Further clarification is necessary and criteria for 
selection are needed to prevent delay in reaching the possible diagnosis 
especially where there are long delays awaiting further investigations. 
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Figure 1.1 The BSG guidelines for investigation of patients with IDA[1] 
Further investigations 
as indicated 
3 monthly measures of Hb 
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In a study conducted at Leighton hospital, 62 patients who were diagnosed 
with proximal cancer from 1998 to 2001 where analysed. Timeline and 
process of investigation from referral to treatment as well as final stage of 
cancer was studied. We demonstrated a delay in patients presenting with 
proximal colon cancer (PCC) whilst being investigated in hospital [47] (figure 
1.2). 
Figure 1.2: Median delay in days of care pathway of proximal colon cancer patients. 
 
(Bar represents median, vertical line represent range (min-max)) 
This total time to treatment was higher in anaemic PCC patients although 
this did not reach statistical significance (p=0.6 Mann-Whitney U test). There 
was, however, no difference in the proportion of anaemic patients between 
stages of cancer at presentation (p=0.8 chi-square test), (Table 1.5) 
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confirming that anaemia remains a predominant feature of proximal colonic 
cancer regardless of stage.  
 
Table 1.5: Total time in days from referral to treatment of PCC patients and stage of 
cancer. 
 
Median in days 
(95%CI) 
Dukes B Dukes C Dukes D 
Anaemic 55(23-85) 74% 67% 78% 
Non-Anaemic 30(16-118) 26% 33% 22% 
     
Anaemia and blood indices. 
Anaemia is defined as total haemoglobin (Hb) level below the lower limit of 
normal reference range , although the standards can differ from one 
laboratory to the other it is commonly accepted that Hb less than 13grams/ 
dl for men and 11.5grams/dl for women constitutes anaemia.[48]  
Anaemia can be classified according to cause or morphology. 
Classification according to cause will provide a useful blueprint for the basis 
of our hypothesis in later chapters. 
Hence we can group classify acquired causes of anaemia into: 
a. Decreased production of red blood cells or Hb. 
This could be due to deficiency in nutrients essential in Hb and red cell 
production for example iron, vitamin B12 and folic acid or toxicity of 
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bone marrow resulting in reduction of bone marrow red cell 
precursors such as that seen in bone marrow replacement with 
malignant cells (primary or metastatsic) or para-neoplastic supression. 
In anaemia of chronic disease Hb production is restricted due to 
relative iron deficient erythropoiesis due diversion of iron to 
inflammatory response . 
b. Increased destruction of red blood cells. 
This a state where there is loss of red cells due to excessive 
destruction, e.g. haemolytic anaemia, spherocytosis or acute loss such 
as bleeding.  
Deficiency of the essential nutrient Iron is relevant to this study and hence 
we will discuss this further. 
In Iron deficiency there is impairment in the production of Hb as Iron is the 
precursor of the heme molecule. Deficiency of iron does not impair the 
production of red blood cells, except when severe deficiency occurs where 
reduction in red blood cell precursor proliferation occurs. Hence this will 
result in circulating red blood cells having less haemoglobin causing a 
reduction in size and colour (microcytic hypochromic anaemia).  
Iron ions circulate bound to plasma transferrin and accumulate within cells in 
the form of ferritin. They serve as an enzyme cofactor and oxygen carrier 
[49].   
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Adult men normally have 35 to 45 mg of iron per kilogram of body weight 
[49]. Levels are lower in premenopausal women as a result of recurrent 
blood loss through menstruation. The majority of iron is incorporated into 
haemoglobin in developing erythroid precursors and mature red cells.  
Intestinal absorption of iron occurs via the duodenal crypt cells. They sense 
the iron requirements of the body and are programmed by that information 
as they mature into absorptive enterocytes [49]. Enterocytes lining the 
absorptive villi close to the gastroduodenal junction are responsible for all 
iron absorption. A combination of low pH of gastric effluent and reduction of 
ferric iron to ferrous form by brush-border ferrireductase facilitates 
absorption [49]. Heme iron is taken up by a separate process that is not well 
characterised. Heme iron is absorbed more efficiently than inorganic iron by 
the human intestine [50]. Heme enters the enterocyte as an intact 
metalloporphyrin[51]. The absorption of intestinal iron is regulated in several 
ways: 
a. Dietary regulation: based on iron recently consumed in diet which 
causes enterocyte saturation with iron.  
b. Store regulation: This is dependent on iron levels and responds to 
total body iron. 
c. Erythropoietic regulator: Iron absorption changes in response to the 
requirements for erythropoiesis. This regulator has a greater capacity 
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to increase iron absorption than the stores regulator[49]. The 
mechanism of how this control is achieved is unknown.  
Haemoglobin production is untroubled until iron stores are depleted, as 
reflected by low serum ferritin levels[49] . This results in iron deficient 
erythropoiesis when the stores have been used up, and the iron saturation of 
transferrin decreases[52]. There is also a rise in free protoporphyrin in red 
cells. The levels of soluble transferrin receptor, a protein-cleavage product 
that is present in plasma, increase when iron deficiency limits the production 
of new red cells. Anaemia with microcytosis is the last event (Table1.6).  
A decreased reticulocyte Hb level is a useful early indicator of iron-deficient 
erythropoiesis and may be superior to other laboratory measures in this 
respect [53].  
Anaemia of chronic inflammation, also known as anaemia of chronic disease, 
has some features in common with IDA. Iron-deficient erythropoiesis results 
from a defect in iron recycling. Reticuloendothelial iron stores are high in 
macrophages, but this iron is not available to erythrogenesis. Laboratory 
findings may include low serum iron levels, low serum iron-binding capacity, 
increased serum ferritin, and normocytic or slightly microcytic erythrocytes. 
In contrast to patients with IDA, those with anaemia of chronic inflammation 
do not have elevated levels of serum transferrin receptor [54] (Table 1.6). 
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Table 1.6 Phases of iron deficient anaemia and corresponding blood indices.  [48] 
Iron stores Normal 
Storage- iron 
depletion 
Iron-deficient 
erythropoiesis 
Iron-deficient 
anaemia 
Reticulo-Endothelial  
marrow iron 
Present Trace/absent Absent Absent 
Serum Ferritin(μg/l) 15-300 20 10 <10 
Serum Iron(μmol/l) 10-30 20 <10 <7 
Transferrin receptor(mg/l) 2.8-8.5 <8.5 >8.5 >8.5 
Marrow sideroblasts (%) 30-50 30-50 <10 <10 
Red cell Protoporphyrin 
(μmole/mol hb) 
<80 <80 >80 >80 
Red cell production     
Haemoglobin (g/l) 
Normal for Lab 
reference  
Normal for Lab 
reference 
Normal for Lab 
reference 
< Normal for 
Lab reference 
MCV (fl) 80-92 80-92 80 <80 
MCH (g/l) 27-32 27-32 27 <27 
Morphology Normal Normal Normal 
Microcytic 
Hypochromic 
 
It is hypothesised that chronic inflammation processes result in withholding 
iron from microbes as well as from erythroid precursors[55]. Mild anaemia 
may be a relatively small price to pay for the attenuation of infection. Hence 
the only effective treatment for anaemia of chronic inflammation is 
correction of the underlying disorder.  
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Blood Indices.[56] 
A routine full blood count (FBC) will assess red blood cells and their indices, 
white blood cells and platelets. 
Blood indices are: 
a. Measured indices: Hematocrit, Haemoglobin levels, Red blood cell 
count and Red distribution width, or 
b. Calculated: these are calculated from the above indices. They 
include Mean corpuscular volume, Mean corpuscular haemoglobin, 
Mean corpuscular haemoglobin concentration.  
The haematocrit is a measure of the total volume percent formed by the red 
blood cells in a sample of whole blood, also known as packed cell volume. 
The haemoglobin is a measure of how much haemoglobin protein is in the 
blood, expressed in grams/dl.  
The red blood cell count (RBC) measures the number of red blood cells 
present in the unit of whole blood volume, expressed in number x 109 
cells/ml.   
The relationships between the hematocrit, the Hb level, and the RBC are 
converted to red blood cell indices through mathematical formulas. These 
formulas were worked out and first applied to the classification of anaemia 
by Maxwell Wintrobe in 1934[48]. 
Mean corpuscular volume (MCV)  
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MCV is the index most often used. It measures the average volume of a red 
blood cell by dividing the hematocrit by the RBC. The MCV categorises red 
blood cells by size. Cells of normal size ( 80-92 fl) are normocytic, smaller 
cells are microcytic(<80fl) and larger cells are macrocytic(>92fl). These size 
categories can be used to classify anaemia too.  
Mean corpuscular haemoglobin concentration (MCHC)  
The MCHC measures the average concentration of Hb in a red blood cell. 
This index is calculated by dividing the Hb by the hematocrit. The MCHC 
categorises red blood cells according to their concentration of haemoglobin. 
Cells with a normal concentration of Hb are called normochromic; and cells 
with a lower than normal concentrations are called hypochromic. Because 
there is a physical limit to the amount of Hb that can fit in a cell, there is no 
hyperchromic category. 
Just as MCV relates to the size of the cells, MCHC relates to the colour of the 
cells. Haemoglobin contains iron, which gives blood its characteristic red 
colour.  
Mean corpuscular haemoglobin (MCH)  
The average weight of Hb in a red blood cell is measured by the MCH. The 
formula for this index is Hb multiplied by 10 and divided by the RBC. MCH 
values usually rise or fall as the MCV is increased or decreased. 
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Red cell distribution width (RDW)  
The RDW measures the variation in size of the red blood cells. Usually red 
blood cells are a standard size. Certain disorders such as IDA, however, cause 
a significant variation in cell size. It is also a reflection of heterogeneity of the 
population of blood cells. It is the equivalent of the microscopic description 
of poikilocytosis.  
Figure 1.3 Blood films appearance of poikilocytosis 
  
Normal Blood Film Poikilocytosis and hypochromia  
 
Conditions that cause microcytosis could be differentiated using RDW. In IDA 
the RDW rises due deficient erythropoiesis, however in thalassemia the RBC 
population is small but homogenous hence the RDW is relatively lower than 
in IDA. 
The haemoglobin and MCV definition of anaemia and IDA have been 
adapted by the DoH and the BSG. Table 1.7 details the definitions of 
different criteria. 
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Table 1.7 Criteria used for classification of anaemia for referral  
Criteria for classifying anaemia Definition 
i. Anaemia as per laboratory normal value Hb <13 in males, Hb<11.5 in females 
ii. Microcytosis as per laboratory normal  MCV< 82 in males, MCV < 78 in females 
iii. Local definition of IDA Anaemia and Microcytosis as per 
laboratory limits 
iv. Anaemia as per DoH referral criteria Hb <11 in males, Hb <10 in females  
v. DoH Criteria for Iron Deficiency Anaemia  Anaemia as defined by DoH criteria and 
MCV<76 
vi. BSG criteria for IDA Hb less than normal for laboratory and 
MCV <76 or Ferritin < 15 
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Review of common GI pathologies causing anaemia 
 
 
Abstract 
Iron deficiency anaemia (IDA) in the over 45 year olds is commonly caused by 
occult gastrointestinal (GI) blood loss. It is thus recommended to evaluate 
the GI tract as a priority. Pathology identified on investigation of the upper 
and lower GI tract vary in incidence in this population. This review aims to 
evaluate the literature with respect to common causes of chronic blood loss 
identified during the investigation of patients over 45 presenting with IDA.  A 
PubMed search using: anaemia, iron deficiency, gastrointestinal, endoscopy, 
was conducted. Prospective studies reported in the English language were 
retrieved. A further cross reference of bibliography of the selected papers 
and major guidelines papers was conducted to retrieve further studies. A 
total of 18 studies were identified and reviewed. Upper gastrointestinal loss 
is the commonest cause of IDA, accounting for 12-70% of all causes. 
Inflammatory gastritis is the leading cause in the upper GI and overall causes 
of IDA. Gastric and oesophageal cancers are rare causes, (less than 8%). 
Lower GI causes account for 9-56% in all the reports. Colon cancer is the 
leading cause in the lower GI tract and the commonest malignancy causing 
IDA. The incidence increases with age. Pathologies such as hiatus hernia, 
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diverticular disease should be accepted as causes only if all other causes 
excluded and are clinically severe.  
Introduction 
Occult GI blood loss remains the commonest cause of IDA in those over 
45years old[57]. GI investigation identifies a potential source of bleeding in 
up to 85% of the cases [57]. However, the reports vary in what they accept 
as a potential cause of anaemia as some of the described pathologies are 
prevalent in the general population[58].  
This section reviews the literature for studies that reported GI causes of 
anaemia, exploring the relationship between commonly reported 
pathologies and occult GI blood loss. 
Methods 
The review aimed to identify all studies that evaluated patients who 
presented with iron deficiency anaemia and have been assessed at with dual 
upper and lower gastrointestinal investigation as a minimum.  
Search of the PubMed Medline (US National Library of Medicine) was 
conducted using the key words: anaemia, iron deficiency, gastrointestinal, 
endoscopy, and prospective. Only English language papers were selected 
with a publication date up to 2010(Figure 1.4). This search returned a total of 
88 papers.   
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Figure 1.4: Literature review search flow diagram 
PubMed search  Using keywords 
Anaemia, Iron deficiency, 
Gastrointestinal, Endoscopy, and 
Prospective study 
English papers only published up to  2010  
Bibliographic cross citation 
and Review articles and 
published national 
guidelines bibliography 
search 
88 publications 
identified 
Papers were excluded if: 
• Investigated IDA patients could 
not be identified.   
• Highly selective patients are 
investigated (e.g. infected 
population, specific disease 
population),  
• Patient population that is 
premenopausal or under the 
age of 40 years old. 
•  Studies that did not have a full 
colonic and gastroscopic  test 
• Failure to or absence of 
7 papers 
identified 
18 papers 
reviewed  
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Abstracts of the publications were screened independently by two reviewers 
for relevant studies. Exclusion criteria were as follows:  
 Investigated IDA patients could not be separated from the total 
sample; 
 Highly selective patients are investigated (e.g. infected population, 
specific disease population);  
 Patient population that is premenopausal or under the age of 40 years 
old; 
  Studies that did not have a full colonic and gastroscopic evaluation; 
 Failure to describe, or absence of, diagnoses in detail. 
7 publications were identified from the search. The bibliographies of the 
selected publications were then screened for relevant cross citations and 
retrieved. Furthermore, bibliography of recent review articles and national 
guidelines on investigation of iron deficiency anaemia were also screened for 
relevant papers.  An additional 11 publications were identified and included 
in the review. A total of 18 publications were analysed.   
Quality appraisal: All studies were prospective. The population 
characteristics were clearly defined. However some papers were included in 
spite of these potential biases:  
 McIntyre et al[37] 93 out of the 111 patients had complete upper and 
lower GI investigation; 
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 In Landy et al’s study[59] the authors reported only predefined 
diagnosis; 
 Nahon et al had a female only population[60]; 
 Urquhart et al[61] had 5% of the population under the age of 40 and 
did not list the diagnosis in 16% of the upper GI causes and 11% of he 
lower GI causes; 
 Annibale et al[62] had an unknown proportion aged < 40 years; 
 In Joosten et al[63] the population was elderly (>70 years); 
 Urquhart et al [61] and Landy et al [59] had retrospectively analysed 
prospectively collected data. 
Results 
The findings of upper and lower GI investigation were summarised in tables 
1.8, 1.9 and appendix 1.  
Upper Gastrointestinal Tract 
The upper GI tract is the commonest site where a cause of anaemia is 
identified. The incidence ranges from 12-70% in 18 studies reviewed. The 
BSG guidelines reported a 30-50% rate for detection of cause of IDA in the 
upper GI tract[1].  Gastric or duodenal ulcers are the commonest cause of 
anaemia in the upper GI tract, accounting for 7 to 51% of all upper GI causes 
and 2-26% of all causes of IDA . It is also the commonest diagnosis in all 
patients investigated for anaemia (Table 1.8 and 1.9).  
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Table 1.8: Publications reporting diagnosis of causes of iron deficiency anaemia in patients who had upper and lower gastrointestinal evaluation. 
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No of patients with Anaemia 71 80 98 96 100 170 89 96 70 478 111 117 48 749 100 95 6538 100 
Total No of patients with Upper GI causes 14 38 20 55 60 70 51 47 39 56 45 54 14 
 
37 55 918 36 
Gastric or Duodenal Ulcer 7 8 9 25 8 15 10 12 6 17 23 9 1 71 19 23 377 7 
Gastric Cancer 2 1 5 6 5 
 
7 2 3 10 8 7 2 14 1 7 22 1 
Gastritis ( inflammatory or atrophic) 19 2 14 12 14 7 
 
17 11 
 
7 17 9 16 6 16 
 
12 
Oesophagitis 
 
14 
 
11 14 8 26 12 10 4 15 9 2 1 6 7 
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Celiac disease 4 
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3 2 
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Gastric Venous Malformation 
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231 8 
Gastric or duodenal polyps 
 
6 
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4 2 
  
6 
 
1 1 
  
1 
Oesophageal Cancer 
   
1 1 
 
2 
 
1 
         
large Hiatus Hernia or with erosions 5 2 7 
 
7 
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Oesophageal Varices 
    
3 
            
2 
Duodenitis 
            
1 
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H pylori Gastritis 13 
 
15 
               
Other upper GI causes 
 
5 5 
 
10 6 6 
 
2 21 4 
   
1 
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Total No of patients with Lower GI Causes 18 16 27 26 23 30 50 31 21 55 18 31 16 
 
26 10 586 26 
Colonic  Vascular Malformation 3 1 4 2 2 3 2 6 6 11 1 5 3 3 5 
 
251 5 
Colon Cancer 10 7 13 8 14 9 33 13 4 24 5 14 11 25 11 5 116 6 
Colonic Polyp 2 5 4 3 6 
 
8 10 7 18 8 10 5 21 5 1 409 14 
All Inflammatory Bowel Disease 1 1 1 2 3 4 9 1 1 9 2 
  
9 2 1 
  
Colonic Ulcers 
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2 
Piles 
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Severe Diverticular Disease 
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other colonic causes 
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Dual pathology 4 5 
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12 7 2 
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Table 1.9: Literature review summary of incidence of causes of anaemia on endoscopic evaluation of the gastrointestinal tract as investigation for 
iron deficiency anaemia 
 
 
Number of studies 
Combined total number 
of patients from all 
studies 
Range of number of 
patients with diagnosis  
Range of incidence of 
diagnosis in anaemic 
patients (%) 
Range of incidence of 
diagnosis in respective 
site of GI tract (%) 
No of patients with Anaemia 18 9206 48-6538 
  
No of patients with Upper GI causes 17 1645 14-918 12-70 
 
Gastric or Duodenal Ulcer 18 647 1-377 2-26 7-51 
Gastric Cancer 17 103 1-22 0.3-8 2-25 
Gastritis ( inflammatory or atrophic) 15 179 2-19 2-27 5-70 
Oesophagitis 15 145 1-26 0.1-29 7-51 
Celiac disease 7 29 2-11 2-11 4-55 
Gastric Venous Malformation 9 273 1-231 1-8 3-25 
Gastric or duodenal polyps 8 24 1-6 0.1-8 3-16 
Oesophageal Cancer 4 5 1-2 1-2 2-4 
large Hiatus Hernia or with erosions 5 23 2-7 3-7 5-35 
Oesophageal Varices 2 5 2-3 2-3 5-6 
Duodenitis 2 3 1-2 2-2 6-7 
H pylori Gastritis 2 28 13-15 15-18 26-75 
Other upper GI causes 10 553 1-493 1 3-54 
No of patients with Lower GI Causes 17 1010 10-586 9-56 
 
Colonic  Vascular Malformation 17 313 1-251 0.4-9 4-43 
Colon Cancer 18 328 4-116 2-37 19-69 
Colonic Polyp 17 536 1-409 1-14 10-70 
All Inflammatory Bowel Disease 14 46 1-9 1-10 3-18 
Colonic Ulcers 2 4 2-2 2 8-8 
Piles 5 39 1-25 1-6 3-30 
Severe Diverticular Disease 2 8 3-5 3-5 12-19 
other colonic causes 4 13 1-8 1-3 2-17 
Dual pathology 11 82 1-26 1-29  
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Oesophagitis accounts for 12% [37, 39-41, 64-66] of all causes of 
anaemia and 26% of all upper GI causes in investigated patients.  
Hiatus hernia is the commonest upper endoscopic finding in a 
symptomatic population investigated by means of an upper GI 
endoscopy [67, 68]. The incidence ranges from 4% to 28%. Hiatus hernia 
has been reported as a cause of IDA in 7% [39, 57] of patients 
investigated with dual endoscopy and 11% of all upper GI causes of IDA 
(Table 1.9). Anaemia will be present in a subset of patients with hiatus 
hernias [69]. However it is not a common cause of upper GI occult blood 
loss, unless there are erosions or ulcers[57]. The resultant oesophagitis 
and or Barrett’s metaplasia are other mechanism explaining chronic 
blood loss. Cameron identified IDA in 6.9% of patients with 
diaphragmatic hernia [70]. In 41% of patients with anaemia and a large 
hiatal hernia there are associated linear mucosal erosions at the hiatus 
from chronic irritation at the diaphragm, commonly referred to as 
Cameron lesions [71]. In most patients with diaphragmatic hernia and 
associated anaemia refractory to medical treatment, surgical repair can 
result in successful resolution of the anaemia [72].  When a large hiatus 
hernia was identified, it was not the sole factor potentially causing upper 
GI loss [39]. Cook et al reported that in 5 out of 7 large hiatus hernias, 
another concomitant upper GI pathology causing anaemia was identified. 
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Hence hiatus hernia will cause occult upper GI blood loss only if 
complicated with ulcers or erosions. In contrast, large hiatus hernia 
causing IDA was the sole finding in 38 patients investigated for chronic 
blood loss [73]. Cameron lesions were only identified in 50% of these 
patients. The authors hence concluded that the presence of a  large 
hiatus hernia was enough to cause chronic blood loss. 
Gastric and oesophageal cancer are rare, although in patients 
investigated for anaemia the incidence is higher than the general 
population, but they only account for 2 to 8 % of causes[31, 74](table 
1.9).  Oesophageal cancer rarely presents with anaemia and hence the 
majority of upper GI cancers presenting with anaemia are gastric (1-2% 
vs.0.3 to 8% respectively)(table1.9). This is to be expected as before 
oesophageal cancer causes significant blood loss it usually causes 
obstructive symptoms. 
Overall in the upper GI tract inflammatory processes ( gastritis, 
oesophagitis and duodenitis), cancer, polyps and vascular lesions account 
for the majority of causes, while hiatus hernia in the absence of erosions 
rarely causes anaemia.  
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Lower Gastrointestinal Tract 
Lower GI blood loss accounts for 9 to 56% of causes of anaemia (table 
1.9). Colon cancer is the commonest cause of anaemia in the lower GI 
tract [57, 64, 75]. It represents on average 38% of all lower GI causes and 
11% for all causes of anaemia in investigated patients,(ranges from 2% to 
37%)( table1.8,1.9). The majority of these cancers are proximal to the 
splenic flexure [11]. None of the proximal colon cancers in a cohort of 
patients studied by Hodder et al had dukes A [47]. In the elderly 
(>65years old), the colon cancer risk increases significantly. Coban et al 
have identified colon cancer as the most common lesion in the lower GI 
tract and the second commonest cause of anaemia in the entire GI tract 
after inflammatory gastritis[76].  Colonic polyps constitute the second 
commonest cause (10-70% of lower GI causes and 1-14% of all causes) 
followed by vascular malformation and inflammatory bowel disease 
(table1.9).  
Diverticular disease has not been commonly recognised as a source of 
chronic blood loss[77].Two reports( Coban et al[76] and Capurso et 
al[78])  identified diverticular disease without acute bleeding as a cause 
of chronic blood loss.  Coban et al did not describe the characteristics of 
the diverticular disease or the severity. Capurso et al, on the other hand, 
have attributed IDA to diverticular disease only in the presence of 
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positive FOB.  Rupture of the vase recta within diverticular disease is the 
commonest cause of bleeding acutely [79], but it is not entirely clear how 
this phenomenon could cause chronic blood loss.  
Haemorrhoidal disease is only reported as a cause in one study[65]. 
Significant chronic blood loss from large haemorrhoid tends to be 
brought to medical attention.  
In summary colon cancer, polyps, inflammatory bowel disease, 
angiodysplasia and mucosal ulcerations should be regarded as causes of 
chronic blood loss from the lower GI tract. 
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Chapter 2 
Developing prioritisation tools 
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Developing prioritisation tools 
Abstract 
Clinical prediction models are used commonly in medicine. They help 
identify risk, prioritise tests and target interventions in high risk groups. 
This chapter discusses fundamental elements in development of clinical 
prioritisation tools used to streamline tests. These elements consist of a 
clear definition of the problem in question, the factors that help predict 
the outcomes and their interactions. Different statistical methods and 
models are used to generate tools to use in practice to test efficacy and 
translate some of the statistical measurements into practice.   
Introduction 
Health care is at the top of the political agenda and the DoH is currently 
under pressure to meet targets to improve the quality and quantity of 
care delivery, within the confines of a budget.  
Guidelines, prioritisation tools and demand management protocols have 
been introduced to resolve areas of deficiencies in health care. 
Ultimately these tools are aiming to improve quality of health care 
provision and where applicable improve on the outcomes of health 
problems (e.g. survival in cancer, quality of life in joint surgery and 
cataract). 
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The NHS modernisation agency declared core values in the demand 
management protocols. [NHS modernisation agency, 
http://www.natpact.nhs.uk/demand_management]  
 Individuality: Services will be tailored to each individual's needs in 
relation to the type, time and location of the service. 
 Transparency: All decisions concerning care provision will be open 
and transparent. 
 Evidence: Decisions concerning care will be based, wherever possible, 
upon evidence, and if this is not possible consensus. 
 Equity: Services will be provided in an equitable manner. 
 
 Expenditure on healthcare is not a “bottomless pit” and choices have to 
be made in all medical systems. High demand can cause delay and 
jeopardise the health of individuals who most need help. It is thus 
appropriate to prioritise those individuals with the greatest risk and/or 
disability and also provide a mechanism for equitable and consistent 
decision making and access.  
A balance is necessary to optimise the delivery of health care. 
Rationalisation of health delivery is a difficult issue that raises debate 
among patients and health providers. This is an arena for major conflicts. 
Hence prioritisation tools have a very important role to play if we are to 
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reduce these possibilities and at the same time make best use of 
resources. 
This chapter highlights essential concepts in developing such tools. 
Although these appear to be obvious it is surprising how many current 
guidelines have overlooked these fundamentals.   The core structure of 
these basics revolves on evidence based practice. When adhered to 
accurately, not only will it result in efficacy of health care delivery but it 
will also provide a well-controlled source of reliable evidence. 
The development of a demand management tool can be summarised in 
the following steps: 
1. Defining the structure of the tool;  
2. Testing the tool. 
Defining the Structure of the Tool 
A) Defining the outcome 
The outcome is the dependent factor. It is a product of the interaction of 
several independent factors. 
Defining the outcome involves defining what is to be measured, the 
relationship between priority and what is measured, and defining the 
scale used to determine priority. 
The outcome is the reason that we need a priority tool. This could reflect 
symptom severity, quality of life, cancer risk etc. 
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Priority and outcome measures can be related directly or indirectly. For 
example in cancer referrals using a risk prediction tool that produces an 
inference of the chance of cancer will determine priority on a direct 
relationship with outcome (cancer risk). On the other hand, in hip 
surgery referrals using a tool that reflects quality of life will determine 
priority based on lifestyle restriction, not actual hip movement 
restriction. This is an indirect relationship as other factors could 
contribute to poor quality of life.  
Priority could be reported on a categorical scale; binary (e.g. high and 
low risk); discrete multiple (e.g. urgent, soon, routine); or continuous 
scale (e.g. symptom severity score, pain scores etc). 
For a tool to be efficient the outcome measure should be: 
i. A true reflection of an individual’s main concern e.g. symptom 
severity in cataract, cancer risk in colorectal referrals, likelihood of 
proceeding and benefiting from surgery in hip and knee 
replacement. 
ii. If the intervention causes a change then this change must be able 
to be audited e.g. quality of life after joint replacement. 
B) Identifying predictors 
These are independent factors that have a direct relationship with the 
intended outcome. 
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They are the components of the tool. Their power of prediction is 
dependent on the extent of their relationship, and this can be 
assessed statistically by means of uni-variant or multi-variant analysis. 
 It is important to recognise inter-relationships between independent 
variables. Failure to recognise mutually exclusive factors will result in 
duplication in the prediction module, rendering it complex and not 
adding to its power. 
  
C) Defining the relationship 
When independent factors are used to predict an outcome their 
relationship can be defined in the form of a mathematical model.  
The risk factors could simply predict out come in a 1:1 ratio, i.e. if one 
factor is present regardless of the presence of any other factor then risk 
is present. A good example is the DoH colorectal guidelines for referral to 
secondary care which classifies an individual at high risk for cancer 
(dependent variable “outcome”) if one of several risk factors 
(independent factors) are present. Such a simple expression of 
relationship of risk factors rules out the cumulative risk from several 
factors existing simultaneously. In such circumstances it is preferable to 
have a model that allows a cumulative build-up of risk, benefit or 
disability e.g.  Selva Score for colorectal cancer risk[16, 80]. The result of 
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such a tool would be on a continuous scale which allows an accurate 
assessment of likelihood of occurrence of the outcome. Furthermore 
continuous scales allow for threshold adjustments to meet available 
resources. 
The relationship between each independent variable and the dependent 
outcome is not always uniform across the range. Some independent 
factors have a higher power of association than others. This can be 
expressed in the form of weightage. 
Weights to risk factors can be assigned from likelihood ratios, odds 
ratios, relative risks. It can also be derived from multivariate analysis e.g. 
regression analysis. 
When the relationship cannot be defined in an objective manner, e.g. 
patient’s preference, then a utility value can be assigned. This is a weight 
of preference that is determined arbitrarily by consensus of the 
investigators. 
D) Statistical tools 
Careful selection of statistical tools is essential in assessing the 
interaction of dependent and independent factors.  
Choice of tool is based on several factors.  
42 
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i. Uni-variant analysis is used when assessing the interaction between
one dependent and independent factor. e.g. t-test, chi-square test, 
likelihood ratios, odds ratios and relative risks. 
ii. Multi-variant analysis is used when assessing the interaction between
more than one independent and or dependent variables. Examples of 
such tools are multiple regression, logistic regression, factor analysis 
and discriminate analyses 
iii. Neural networks.
Conventional mathematical tools define interaction and fit them to a 
hypothetical line. The majority of the time these are linear 
relationships. Advanced tools such as polynomial regression fit 
multiple linear relationships in succession to produce curved 
relationships. It is apparent that this is not possible all the time. 
New computer technologies have developed neural networks that 
allow for description of interactions in a non-linear form. This has 
been introduced in medical science to identify relationships in a 
supervised fashion, i.e. the outcome is known; or unsupervised 
fashion, i.e. the outcome is unknown. 
Although powerful they need training and must not be abused as data 
mining tools as not all relationships are meaningful[81, 82]. 
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Implementation 
The efficacy and performance of any tool not only depends on its 
intrinsic characteristics but also on its implementation. Production of 
a tool that is not easily implementable will render it ineffective and 
incapable of achieving its main goal. It should have a mechanism that 
transmits the true distribution of risk factors independent of 
confounding factors. 
 Considering this at the early stage in development allows us to choose 
between alternatives in the factors in the tool which will make it 
easier to use and apply. 
In summary an ideal tool must be practical and easy to implement, 
constructed with inclusion of accurate and powerful predictors of 
outcome expressed in a model that allows a cumulative assignment of 
risk and gives each risk factor a weight in proportion to it is power of 
relationship to the outcome. 
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Testing the Efficacy 
In health research the efficacy of a testing tool for decision making is 
determined by accuracy indices. These are defined as: 
1. Sensitivity: how good is a test in detecting the disease in the diseased 
population? 
2. Specificity: how accurate is the test in correctly identifying those with 
no disease in the healthy population? 
3. Positive predictive value: how accurate is a positive test result? i.e. 
how many of those who have a positive test have the disease. 
 
Table 2.1 Calculation of sensitivity and specificity  
 
Test Disease present Disease absent 
Positive A B 
Negative C D 
 
Sensitivity = a / (a+c) 
Specificity = d / (b+d) 
Positive Predictive value= a / (a+b)  
Total positive rate = (a+b) / Total 
 
1- Sensitivity: 
The first step in evaluating the efficacy of a prioritisation 
mechanism is to see if it has met the minimum accuracy in 
detecting those who would be most likely to benefit (sensitivity). 
When developing the tool a minimum sensitivity needs to be 
determined, i.e. we should determine the maximum tolerable 
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proportion of individuals who are true beneficiaries from the 
prioritisation tool but have been missed i.e. minimum acceptable 
or unavoidable failure. 
For example, in colorectal referrals, the minimum set sensitivity is 
90%. This means that 90 % of the patients who have cancer must 
be prioritised correctly using any tool; i.e. the maximum tolerable 
proportion of patients with cancer that are missed is 10%. 
A prioritisation tool that is unable to meet the set standard of 
sensitivity automatically should fail. 
In circumstances where sensitivity is not known, then a consensus 
that sensitivity should be decided on by extrapolation from other 
targets or prevalence of disease. It could be determined from pilot 
observational studies in real or virtual environments with set gold 
standards.   
Having a set sensitivity is vital for assessing performance of a tool 
and essential in a systematic comparison of other tools. 
2- Specificity and Management of Demand 
Specificity is the main indicator of the effectiveness of demand 
management. 
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When prioritising a population; the higher the specificity of the 
tool, the higher the proportion of those who are true beneficiaries 
will be - achieving the highest efficiency of the tool. 
Provided that a tool achieved the minimum acceptable sensitivity 
then it could be preferred over others if it has a better specificity - 
in keeping with the concept of demand management. 
The relationship between these factors determines the strength of a 
testing tool. 
The sensitivity and specificity are not the only important factors affecting 
this relationship. The prevalence of the disease in the population is an 
important factor in determining how a test can perform. The holistic 
interaction can be described in the form of the Bayes’ theorem:  
 
 
Probability of a patient with 
a positive result having 
disease 
= 
Sensitivity x Disease prevalence 
(Sensitivity x Disease prevalence) +[(1-Specificty ) x (1-Disease 
incidence)] 
 
 
The denominator can be converted to the total positive rate of a test 
(prevalence of a positive test in the tested population). Thus the final 
equation would then be: 
Probability of a patient with a 
positive result having disease 
= 
Sensitivity x Disease prevalence 
Total Positive rate 
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Demand management can be defined in a similar context.  
The prevalence of a specific health problem in the population could be 
the prevalence of “disease”.  Sensitivity would then be the efficacy of a 
tool which categorises those who have “disease” and would be in a 
position to benefit.  Specificity would then be the efficacy of the tool to 
eliminate those who were falsely categorised as being able to benefit.  
Total Positive Rate would be the total of the population classified as 
“important” (truly and falsely) i.e. the demand created by the 
prioritisation tool. The positive predictive value would then reflect the 
proportion of those who truly benefited from being given priority, i.e. the 
positive yield or effectiveness of the tool, which is important for cost 
effectiveness. 
 The final relationships could be defined as  
 
Effectiveness  
Accuracy of prioritisation tool  x Prevalence 
Created Demand by the tool (which is dependent on 
specificity and sensitivity ) 
 
In summary effectiveness of a priority tool is directly proportional to the 
accuracy of prioritisation tool and inversely proportional to the created 
demand. Effectiveness is also higher when the relevant problem is 
common, i.e. the yield of a test would be high in spite of a lower accuracy 
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of a test. In contrast, in the situation where the prevalence of the health 
problem in question is low, an efficient tool in using allocated resources 
is reliant on a very accurate tool. For instance in breast cancer, a 
mammogram has a 41% sensitivity, 98% specificity to detect breast 
cancer in all women. As the incidence of breast cancer decreases with 
decreasing age the positive predictive value also decreases (i.e. the 
number of patients with cancer who had a positive mammogram) from 
14% to 8% in those younger than 50 years. [83]  
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Chapter 3 
Hypothesis and study design 
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Aims, hypotheses and study designs. 
This thesis will investigate the benefit and possible use of diagnostic and 
symptomatic indices in streamlining those presenting with anaemia 
(primarily suspected to be iron deficient) in an attempt to predict site of 
cause of anaemia with reasonable accuracy. 
Hypotheses 
1. GI cancers present with different patterns of anaemia; 
2. Blood indices can be used to differentiate cause of possible site of 
anaemia; 
3. Symptom combinations can help in prediction of site of GI 
pathology; 
As result of these hypotheses the ultimate hypothesis of this doctoral 
thesis is:  
In patients presenting to secondary care with IDA for investigation, 
the combination of full blood count indices and symptom profiles 
can be used in a risk tool modelled to predict the likely site of cause 
of IDA.  
Study design 
To test the hypotheses several studies were conducted  
1. Identifying independent factors that can be used in developing a 
prediction tool; 
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a. Study of haematological profiles of common GI malignancies 
(Chapter 4);  
b. Prospective study of a cohort of patients referred with IDA, 
analysing their presenting symptoms and blood indices 
profile and their relationship with diagnosis and site of cause 
IDA (Chapter 5). 
2. Design of a streamlining tool to predict likely site of cause of 
anaemia to aid in prioritising method of investigation. Comparing 
the prediction model and available current practice guidelines 
(Chapter 6).   
a. Primary outcome 
i. Accuracy of prediction of site of pathology 
b. Secondary Outcome 
i. Performance of tool against current guidelines  
ii. Stage of colon cancer as compared to pre and post 
protocol. 
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Chapter 4 
Profile of anaemia in common 
GI malignancies  
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Profile of anaemia in common GI malignancies  
Abstract 
Iron deficiency anaemia (IDA) accounts for 3-14% of referrals to 
gastroenterology clinic. This is due to the high risk of GI cancer as a cause 
for chronic blood loss. Published guidelines for the investigation of 
anaemia aim to reduce the delay of diagnosis of patients with GI cancer.  
However, these guidelines differ in the definition and threshold of 
anaemia to trigger a referral. Furthermore, there is difference in 
presentation patterns of anaemia in colon cancer, with proximal colon 
cancer (PCC) presenting with IDA.  
We aim to study the difference in pattern of anaemia between proximal 
colon cancer and common upper GI cancers and sensitivity of different 
guideline thresholds of referrals.  
Over a three year period, between 1999 and 2001, patients referred with 
proximal colonic cancers, gastric and oesophageal cancers were studied 
and haematological profiles recorded. 
Statistical analyses was performed using, t test, Mann-Whitney U test,  
ANOVA and Chi square test where appropriate. 
159 (61 PCC, 43 gastric, 55 oesophageal) cancers were diagnosed during 
this period. Anaemia was significantly more prevalent in colon and 
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gastric cancers (75% & 67% respectively) as compared to oesophageal 
cancers (27%, p<0.0001). 
Among anaemic patients colonic cancers had a significantly lower mean 
MCV and MCH (74[SD10] & 23[SD4] respectively) as compared to upper 
GI cancers. (Gastric 81[SD9] & 26[SD4], Oesophageal 80[SD9] & 26[SD4]). 
(p < 0.01).  A higher proportion of PCC fulfilled the referral guidelines as 
compared to upper GI cancers. As the referral criteria became more 
specific the sensitivity to cancer detection decreased across all three 
cancer groups.   
Different haematological profiles of GI cancers have been demonstrated. 
Using these profiles we could predict likely site of cancer. In order to 
detect a higher proportion of cancers the thresholds of referral need to 
be lowered.  
Introduction 
Anaemia and IDA in particular, is common in general practice especially 
in the aging population. It is estimated that 2 -5 % of adult men and 
postmenopausal women have IDA[1]. IDA is used as high risk criteria for 
urgent referral to secondary care. However it is not known what 
proportion of these patients attend secondary care for investigation.  
It is estimated that 4-13% of referrals to a gastroenterology clinic are due 
to IDA [1]. Chronic blood loss from the GI tract commonly presents with 
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iron deficiency anaemia (IDA)[1, 38, 84]. Causes of such blood loss are 
vast, however GI malignancy remains the most significant [38-40, 42, 85, 
86]. To avoid delay in diagnosis of asymptomatic colon cancer and upper 
GI cancer[5, 7, 10] the BSG [1],the DoH and NICE  set guidelines in an 
attempt to optimise the investigation of patients who present with IDA 
and highlight those patients at high risk that required urgent referral. 
Recent audits of these guidelines however have not demonstrated any 
improvement in early cancer detection or stage of cancer. There is also a 
high proportion of GI cancer coming through routine referral 
pathways[19, 21, 87]. These problems were attributed to poor sensitivity 
and specificity of IDA to cancer, poor guideline compliance and 
thresholds set too low for referral (i.e. referral if HB < 10g/dl and 11 g/dl 
for women and men respectively). In addition there are conflicting 
reports on the association of cancer stage and anaemia with a tendency 
for anaemia being a late sign of cancer thus questioning the survival 
benefits of using anaemia as the diagnostic tool for detection and 
improving GI cancer survival[88]. 
Prior studies have reported that colon cancers have variable presentation 
profiles (e.g. PCC more commonly presents with IDA as compared to 
distal colon cancer(DCC)) and that the use of red blood indices can help 
in identifying the site of colonic cancer [11, 89, 90], but to date no 
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studies have specifically assessed the pattern profiles of upper GI 
cancers, and colon cancers with anaemia.  
The aim of this study is to identify the differences in full blood count 
indices in the three common GI cancers and whether it is possible to 
differentiate between the proximal colon, gastric and oesophageal 
cancers based on blood indices profile.   
Methods.  
Hospital records were retrieved for consecutive patients diagnosed with 
PCC (caecal, ascending and transverse colon cancer), gastric cancer, and 
oesophageal cancer over a three year period from 1999 to 2001. A total 
of 61 patients with proximal colon cancers (PCC), 55 oesophageal, and 43 
gastric cancers were identified and studied.  
Haematological profiles from the FBC were assessed at the time of 
referral, diagnosis or up to 6 months prior to diagnosis in cases when iron 
or blood transfusions had been administered. Haemoglobin (Hb), 
Haematocrit (Hct), Red Blood Cell count (RBC), Mean Corpuscular 
Volume (MCV), Mean Corpuscular Haemoglobin (MCH), Mean 
Corpuscular Haemoglobin Concentration (MCHC) and Red Distribution 
Width (RDW) were recorded.  
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Anaemia was accepted as < 11.5g/dl in women and < 13g/dl in men. The 
incidence of anaemia and patterns of blood indices were recorded and 
assessed for each GI cancer group.  
Cancer detection rate comparisons were then conducted using the 
laboratory normal range, DoH guidelines, and BSG guidelines (Table 4.1). 
Statistical analysis was conducted using the t-test, Mann-Whitney U test, 
ANOVA and Chi-square test as appropriate.  NCSS software (Kaysville, 
Utah, USA) was used to perform the analysis. P value of <0.05 was 
accepted as statistically significant.  
Table 4.1: Criteria used for classification of anaemia for referral 
Criteria for classifying anaemia Definition 
i. Anaemia as per laboratory normal 
value 
Hb <13 g/dl in males, Hb<11.5 g/dl in 
females 
ii. Microcytosis as per laboratory 
normal  
MCV< 82 fl in males, MCV < 78 fl in 
females 
iii. Local definition of IDA Anaemia and Microcytosis as per 
laboratory limits(Hb <13 g/dl and MCV< 
82 in males, Hb<11.5 g/dl  and MCV< 78 
in females 
iv. Anaemia as per DoH referral criteria Hb <11 g/dl in males, Hb <10 g/dl in 
females  
v. DoH Criteria for Iron Deficiency 
Anaemia  
Anaemia as defined by DoH criteria and 
MCV<76 fl 
vi. BSG criteria for IDA Hb less than normal for laboratory and 
MCV <76 fl or Ferritin < 15 ng/ml 
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Results 
A total of 61 proximal colon (PCC), 55 oesophageal, and 43 gastric 
cancers were identified. There were no significant differences in the 
distribution of age and gender. (Table 4.2) 
Table 4.2:  Patient Demographics and full blood count profiles for cancer types 
  PCC 
Gastric 
Cancer Oesophageal Ca Total P 
Count 61 43 55 159   
Male(%) 30 (49%) 29 (67%) 33 (60%) 92 (58%)   
Female(%) 31 (51%) 14 (33%) 22 (40%) 67 (42%)   
Age(SD) 74.2 (11) 72.2 (11) 74.2 (10) 73.6 (11) 0.6 
Hb(SD) 10.1(3) 10.8 (3) 12.8 (3) 11.2 (3) <0.01 
Count anaemic (%) 46 (75%) 29 (67%) 15 (27%) 90 (57%) <0.01 
RBC(SD) 4.2 (0.6) 4 (0.7) 4.5 (0.7) 4.2 (0.7) <0.01 
MCV(SD) 77.6 (10) 82.4 (8) 85.6 (7) 81.7 (9) <0.01 
MCH(SD) 24.2 (5) 26.6 (4) 28.6 (3) 26.4 (5) <0.01 
MCHC(SD) 311.6 (25) 319.7 (28) 332.1 (22) 320.9 (26) <0.01 
HCT(SD) 32 (6) 32.8 (6) 38.7 (7) 34.5 (7) <0.01 
RDW(SD) 16.2 (3) 15.1(2) 14.3 (2) 15.3 (2) <0.01 
 
The mean Hb was significantly lower in PCC and gastric cancer as 
compared to oesophageal cancer (Table 4.2). The pattern of all blood 
indices was significantly different between all cancer groups. PCC had a 
tendency to present with low MCV, MCH, MCHC, (ie microcytosis and 
hypochromia that is classically seen in iron deficiency anaemia) and a 
high RDW. Both gastric and oesophageal cancer overall had a normal 
MCV, MCH, and MCHC.  (Table 4.3) 
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Table 4.3 Sub analyses of the anaemic cancer patients.  
Anaemic Cancers 
PCC Gastric Cancer 
Oesophageal 
Cancer Total P 
Count 46 29 15 90   
M
e
an
 v
al
u
e
s 
Age(SD) 75.3(10) 73.3(10) 80.1(9) 75.5(10)   
Hb(SD) 9.1(2) 9.4(2) 9.4(2) 9.2(2) 0.7 
RBC(SD) 4(0.6) 3.7(0.5) 3.8(0.6) 3.9(0.6) 0.04 
MCV(SD) 74.4(10) 81.4(9) 80.1(9) 77.6(10) <0.01 
MCH(SD) 22.5(4) 25.6(4) 25.1(4) 23.9(4) <0.01 
MCHC(SD) 302.9(23) 310.4(29) 311.1(28) 306.7(26) 0.3 
HCT(SD) 29.5(5) 29.7(4) 30.7(5) 29.8(5) 0.7 
RDW(SD) 16.9(3) 15.7(2) 15.7(2) 16.3(3) 0.1 
  
Anaemia is a significantly common feature of both gastric and proximal 
colon cancer as compared to oesophageal cancer. Although a higher 
proportion of PCCs present with anaemia as compared to gastric cancers, 
this difference did not reach statistical significance (p=0.8).  
When the anaemia threshold was adjusted to the current DoH guideline 
recommendations (Table 4.4), the proportions of cancers detected 
reduced. This was compounded by using the addition of microcytosis 
(low MCV) resulting in a further reduction of sensitivity for each cancer 
group.  
Table 4.4: Percentage of cancers fulfilling guideline’s referral threshold criteria.  
Criteria for anaemia (Criteria 
number in table 4.1) PCC Gastric Cancer 
Oesophageal 
Cancer Total 
Count 61 43 55 159 
Lab anaemia (i) 75% 67% 27% 57% 
DoH anaemia (iv) 56% 51% 16% 41% 
       
Lab Microcytosis (ii) 54% 40% 18% 38% 
BSG Microcytosis (vi) 44% 21% 7% 25% 
       
IDA (iii) 52% 33% 13% 33% 
BSG IDA (vi) 44% 19% 7% 25% 
DoH IDA (v) 39% 16% 7% 22% 
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However, among the different definitions for IDA, the local thresholds of 
anaemia and microcytosis (Hb and MCV less than the laboratory normal) 
had the highest sensitivity for each cancer group. 
Discussion 
 
This study highlights the significant difference in the blood indices profile 
of the common GI malignancies.  
Investigations of both the upper and lower GI tract in patients with IDA 
have commonly yielded a higher incidence of upper GI causes [37, 64, 
91]. However, colon cancer remains the most common cancer identified 
in these patients.  
Studies of the value of blood indices in predicting colon cancer yielded a 
potential for differentiating PCC from distal colonic cancer [89, 90]. This 
study demonstrates a potential of differentiating upper and lower GI 
cancer using the full blood count indices. The higher incidence of 
anaemia, the low MCV and abnormal RDW in proximal colon cancer as 
compared to upper GI cancers confirm that proximal colon cancer results 
in iron deficiency pattern more commonly than upper GI cancer.  
Spell et al [89] demonstrated that a higher RDW is sensitive to PCC even 
in the absence of anaemia. IDA in PCC could be explained by the fact that 
blood loss from proximal colon cancer is often occult and as it passes 
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through the colon there is no potential re-absorption of digested iron or 
heme. In contrast upper GI pathologies have the potential for a 
significant degree of re absorption of heme iron, the most bioavailable 
form of iron [92]. In upper GI cancer presenting in more brisk bleed 
(melaena), the blood index profile would be of acute haemorrhage hence 
the MCV and RDW remains normal.   
Ferguson et al [93] demonstrated in a study using whole gut lavage as 
investigation of chronic blood loss that colonic cancer was the main 
pathology that resulted in a significant detectable blood loss as 
compared to subjects with a confirmed upper GI pathology expected to 
cause iron deficiency anaemia. This questions the causal relationship of 
IDA and upper GI pathology and raises the possibility of other 
mechanisms of cause of IDA in these subjects.  Potential causes of IDA in 
upper GI cancer could be as a result of chronic malnutrition, co-existence 
of systemic disease, paraneoplastic phenomenon in addition to the 
presumed longstanding blood loss. 
In the presence of normal oral intake and absorption of iron the balance 
between blood loss and iron intake determines the onset and severity of 
anaemia in PCC. Hence before anaemia develops, there is a stage of iron 
deficient haematopoiesis. In this situation the population of cells 
produced would be heterogeneous resulting in the raised RDW before 
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anaemia develops.  Once the iron stores are depleted (low ferritin), the 
bone marrow continues to produce RBCs in the absence of adequate 
haemoglobin synthesis resulting in a drop in the haemoglobin contents 
of RBC (low MCH), and low hematocrit with a normal RBC count (low 
MCV). Ultimately this will slow erythrogenesis causing a drop of RBC 
count.  
The use of different criteria as thresholds for high risk referral (Table 4.4) 
has demonstrated a difference in sensitivity for cancer detection. The 
pathogenesis of anaemia caused by GI cancer as described above 
explains the reduction of sensitivity to cancers when the thresholds of 
referrals are changed. Although there is no evidence to support the 
potential improved survival from detecting cancer referred with IDA 
early [89, 90], it is logical to use lower thresholds as criteria for referral 
so that the proportion of cancer detected is increased thereby increasing 
the potential of detecting early disease.  
In summary, GI cancers have different anaemic profiles that have a 
potential to be used in streamlining investigation. The threshold of 
current guidelines needs to be adjusted to increase the yield of cancer 
detected in patients who develop anaemia.  
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Chapter 5 
Prospective study of symptoms, blood 
profile and diagnosis of patients referred 
with anaemia for investigation 
  
 
64 
 
6
4
 
 
Prospective study of symptoms, blood profile and diagnosis of patients 
referred with anaemia for investigation 
 
Abstract 
Unexplained iron deficiency anaemia in men over the age of 40 and 
postmenopausal women is usually related to  gastrointestinal chronic 
blood loss. Often these pathologies have associated symptoms, that if 
present, aid in the direction of investigation. Different blood indices 
patterns secondary to blood loss from the GI tract and systemic causes 
have been recognised (Chapter 4) . The aim of this study was to 
investigate the distribution of presenting symptoms and blood indices 
profiles in patients investigated for unexplained iron deficiency anaemia.  
Over a two year period, patients referred to a dedicated anaemia clinic 
with iron deficiency anaemia were included for data collection. Symptom 
profiles and blood indices were collected. All patients had the GI tract 
investigated by means of upper and lower GI endoscopy with or without 
barium enema. All patients were followed up for a minimum of 1 year.   
125 patients were included in the final analysis.  The mean age was 72.3 
years old (SD 11.4), with 51% of the cohort being males. 34% were 
referred urgently by the GP. Upper GI endoscopy was completed in 94% 
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of the patients and lower GI evaluation by means of barium enema, 
colonoscopy or flexible sigmoidoscopy or combination of any was 
completed in 92%. There was poor compliance with faecal occult blood 
(FOB) testing. A final diagnosis was established in 95% of the patients 
with only 6 patients having completely normal GI tract investigations and 
no other cause of anaemia identified. In these 6 patients the anaemia 
resolved with iron replacement therapy (nutritional cause). Upper GI 
causes were the commonest cause of anaemia (40%) followed by 
systemic (30%) and then colonic (14%). Diverticular disease and gastritis 
were the commonest abnormalities identified. 21 patients (16%) had GI 
cancers with colonic cancer being the commonest (17 patients). 16% of 
the cohort had pathology at two sites or more.  Dyspepsia and heart 
burn were the commonest upper GI symptoms. Dysphagia was rare but 
had the highest PPV for upper GI causes. Other symptoms did not have a 
high PPV for pathology or cancer. The mean Hb was 106 g/l (SD 15.2). 
Patients with cancer had lower Hb, MCV, and HCT. Patients with lower GI 
pathology had a trend towards a lower Hb, MCV, and MCH.  
Individual symptoms did not aid in predicting a site of blood loss. In 
contrast, blood indices helped in predicting site of blood loss. There was 
a poor compliance with referral guidelines.     
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Introduction 
DoH criteria for urgent referral for suspected upper and lower GI cancer 
use anaemia with or without a group of GI symptoms as high risk for 
cancer. Lower GI symptoms have a better cancer predictive value as 
compared to upper GI symptoms [16, 74, 80]. However, both symptom 
groups have poor specificity (as discussed in previous chapter).  
GI tract investigations carry a relative risk of morbidity in view of the 
invasive nature of the tests. Hence it would be prudent to increase the 
specificity of any tool to reduce the unnecessary GI tract 
instrumentation. 
A prioritisation tool that uses the combination of predictive power of 
both symptoms and blood profile to identify the probability of cause of 
anaemia would help streamline patients to the appropriate test thereby 
decreasing the risk of unnecessary investigation. In order to develop such 
a tool, the diagnostic value of presenting symptoms in this population 
and blood profile needs to be established.   
We aim in this chapter to identify the diagnostic value of GI symptoms 
and blood profiles in predicting the site of GI pathology of patients 
referred for investigation of unexplained anaemia.  
Study design and methods 
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Over a 2 year period from October 2003 to October 2005 patients 
referred to the hospital for investigation of IDA were included into the 
study. All patients were interviewed in a dedicated anaemia clinic. 
The anaemia clinic was conducted by the main author (M Ballal), assisted 
by a nurse practitioner. Two other clinicians (D Smith, H Ballal) provided 
cover when the author was unavailable. They received appropriate 
training to ensure consistency and adherence to clinic protocol. The clinic 
was conducted once a week.  
When a patient was referred by their general practitioner (GP) to general 
surgery clinic or to one of the gastroenterology consultant’s clinic (Dr J 
MacKay) for investigation of unexplained IDA, the referral was directed 
to the dedicated anaemia clinic. The usual practice was for the GP to 
classify the referral as urgent (i.e. to be seen within two weeks), soon 
(within 6 weeks), or routine.  Patients’ symptoms and physical 
examination findings were recorded using a structured history and 
examination proforma (Appendix 2). The proforma was used to 
standardise the information gathered and aided in ensuring all patients’ 
relevant tests and investigations were booked into the hospital system. 
Patients had a FBC, iron studies, Folic acid and B12 measured. They were 
also requested to provide a 3 separate stool samples for guaiac-based 
FOB test and urine collected for urinalysis.   
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Patients who were younger than 45 years, or  who had been commenced 
on iron prior to blood analysis, or those  who were unfit for investigation, 
or those who did not give consent for investigation, or who did not 
complete their GI investigations were excluded from the study.   
All patients had an  upper GI investigation in the form of an OGD 
(oesophago-gastro-duodenoscopy) with biopsies where indicated,  and 
lower GI investigation in the form of an endoscopic examination (flexible 
sigmoidoscopy or colonoscopy), barium enema or both  in cases where 
one was incomplete (caecum not fully assessed).  The order of the 
investigations was decided by the reviewing clinician based on clinical 
judgement at the time of testing and availability of investigation slots. 
Any biopsies taken were performed by the endoscopist based on findings 
at the time. Duodenal biopsy was requested as a routine, however it was 
not performed routinely due to variation in endoscopist preference.  
If no cause for the IDA was identified in the GI tract then an assessment 
by haematologist was carried out.  When a diagnosis was not established 
a FBC was repeated and if anaemia resolved no further intervention was 
carried out. However, if anaemia was persistent then a lower GI 
assessment is repeated with an alternative modality.  
Patients where followed up for a minimum of 1 year. 
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Statistical analysis was conducted using NCSS (2004) software (Kaysville, 
Utah, USA). The t- test, Mann-Whitney U test, Chi –Square test, Fisher 
Exact test were used for test of significance where appropriate. P value 
of <0.05 was used as significant. Due to the large number of independent 
variables interrogated in this study a Bonferroni correction for multiple 
testing was considered. The corrected level of significance based on this 
is a  P value of < 0.00012.    
Sample Size 
This is a prospective pilot study that aims to develop a tool to investigate 
patients presenting with IDA. The results will form the foundation of a 
larger trial to validate the developed tool.  
An accurate representative sample of the population of IDA patients 
referred to secondary care is required. Based on literature review it is 
expected that 70 % (95% CI 60-80) of the investigated anaemic 
population will have a GI cause of anaemia (Chapter 1, table 1.8).  To 
obtain a representative sample of the investigated population with a 
type one error probability of 5% a minimum of 81 anaemic patients is 
needed.   
Based on previous reports the cancer detection rate varies from 5% to 
37%. To achieve a cancer detection rate of 14 % (95%CI 8-20%) (Chapter 
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1, table 1.8) then it would require 100 anaemic patients to be 
investigated with a maximum of type one error probability of 5%. 
Hence a minimum of 100 patients is required to have a representative 
sample of the IDA population referred to secondary care.   
 
Results 
A total of 147 patients were referred during the study period for 
investigation.  22 were excluded from the study, 4 were not anaemic 
(that is referred in error), 8 were unfit for assessment, 3 had been 
commenced on iron at the time of referral, 5 were younger than 45 years 
and 2 did not give consent.  
Thus 125 patients were eligible for inclusion into the analysis. Three 
patients whose anaemia had resolved prior to referral but had remained 
either microcytic or iron deficient at time of investigation and  were 
included.  
Demographics 
The average age of patients studied was 72.3 (SD 11.4) ranging from 45 
to 90 years old and a median of 74.4. 
Gender distribution was equal (p=0.9) with 51% (95% CI 40-58%) male 
patients. The age distribution was equal between gender groups (p=0.5) 
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with the age of females averaging 71.6(SD11.4) and males 72.9(SD11.6) 
(figure 5.1). 
  Figure 5.1: Box plot for age distribution and gender. 
 
Urgent referrals as stated by the GP accounted for 34% of the total and 
the remainder 66% of our subjects were referred routinely. 
Investigation modalities 
Upper GI Endoscopy: 
Upper GI endoscopy was performed on 117 (94 %) of the referred 
patients.  Of the remainder, 5 (5%) had a colon cancer identified prior to 
date of endoscopy and the patients did not wish to proceed with an OGD 
and 2 (1%) had overt other causes (1 bladder cancer and renal failure, 1 
hypothyroidism).   
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A Helicobacter pylori urease test via a gastric biopsy was completed 73% 
of the time with a 26% positive rate. Gastric and low duodenal biopsies 
were performed in 25% with a 51.7% positive rate for gastric or duodenal 
pathology. Coeliac disease screening was only performed in suspected 
patients as the hospital did not fund the test routinely.  
Lower GI Investigations: 
Table 5.1 demonstrates the combinations of diagnostic modalities of 
lower GI tract. The entire lower GI tract was visualised in 92% of the 
patients; 8 had flexible sigmoidoscopy only and 3 underwent a CT scan 
and no intra-luminal assessment.   
Table 5.1: Mode of investigation of lower gastrointestinal tract 
Modality of assessment of Lower Gastrointestinal tract Count(%) Mean Age 
Flexible Sigmoidoscopy and Barium enema 63(51%) 72 
Colonoscopy 19(15%) 72 
Barium enema 14(11%) 74 
Flexible sigmoidoscopy, Colonoscopy and Barium enema 8(6.5%) 67 
Flexible sigmoidoscopy 8(6.5%) 77 
Colonoscopy and Barium enema 6(5%) 74 
Flexible sigmoidoscopy and Colonoscopy 4(3%) 74 
CT scan 3(2%) 75 
 
A combination of flexible sigmoidoscopy and barium enema was the 
commonest modality of investigation of the lower GI tract followed by 
colonoscopy alone. The population investigated was elderly and hence 
colonoscopy was chosen only for those patients who were considered 
medically fit enough to have such an invasive procedure. If a pathology 
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was encountered on flexible sigmoidoscopy that required evaluation of 
the reminder of the colon a colonoscopy was  performed if assessment 
revealed the patient to be medically fit. Lower GI tract was evaluated by 
means of a CT scan in 2% of the patients who could not tolerate bowel 
preparation. 
Faecal Occult Blood test (FOB): 
Compliance with FOB testing was poor. FOB was returned by 25% (31) of 
the patients. FOB was positive in 6% of the total cohort and 25% of the 
submitted FOBs (Table 5.2).  
In patients who submitted FOB samples, 29% of patients who had upper 
GI pathology tested positive for occult blood, 43% of patients with lower 
GI pathology tested positive for occult blood. None of the patients with 
non-GI pathologies had a positive FOB test. Of all patients with GI 
cancers only one patient who had PCC submitted a sample for FOB 
testing and tested positive for all three samples.  
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Table 5.2: Faecal occult blood and site of cause of anaemia. 
FOB Total 
Upper GI 
pathology 
Lower GI 
pathology 
Non GI 
causes 
of 
anaemia 
Upper GI 
cancer 
Lower GI 
Cancer 
Positive 8 6 3 0 0 1 
Negative 23 15 4 6 0 0 
Not done 94 43 24 35 4 13 
Total 125 64 31 41 4 14 
 
 Diagnosis  
A cause of anaemia was established in 119 (95%) of the patients, table 
(5.3). 6 patients had a completely normal gastrointestinal tract and a low 
serum iron with anaemia resolving following iron administration. At the 1 
year follow up of these patients no additional GI tract pathology had 
been diagnosed. Anaemia was attributed to iron nutritional deficiency.   
 
Table 5.3: Final diagnosis in all patients investigated.  
Final Diagnosis No. of patients 
Alcoholic Liver Disease(ALD)and Duodenitis 1 
ALD and Hiatus hernia (HH) 1 
ALD+ Helicobacter Pylori (HP) Gastritis+ Oesophagitis+ Distal Colonic Polyps 1 
Anaemia of chronic disease 1 
Anaemia of chronic disease and HH and Severe Diverticular disease(DD) 1 
Auto-immune PGAD 1 
Barrett’s Oesophagus and Mild DD 3 
Barrett’s Oesophagus, Chronic Gastritis, Thalassemia 1 
Barrett’s Oesophagus, duodenitis and Mild DD 1 
Cholangiocarcinoma, HP gastritis 1 
Chronic Renal Failure (CRF) 2 
Chronic Renal Failure and D polyp 1 
Chronic Renal Failure and Duodenitis 1 
Chronic Renal Failure and HH 1 
Chronic Renal Failure and Mild DD 1 
Distal Colonic Cancer 4 
Distal Colonic polyp 1 
Duodenitis and HH mild DD 1 
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Duodenitis, H Pylori mild DD 1 
Gastric Cancer 3 
Gastric Dysplasia and Distal Colonic Polyp 1 
Gastric polyp AND  mild DD 1 
Gastric polyps 1 
Gastric Ulcer 1 
Gastric Ulcer and Mild DD 1 
Gastritis 3 
Gastritis , Mild DD 5 
Gastritis and Colitis 1 
Gastritis and Distal Colonic Polyps 1 
Gastritis and HH and Mild DD 1 
Gastritis and Mild DD 1 
Gastritis and Oesophageal Varices 1 
Gastritis, mild DD and Distal Colonic Polyp 1 
H Pylori and HH 1 
H Pylori and Oesophagitis and Mild DD 1 
H Pylori Gastritis and Mild DD 1 
H Pylori Gastritis, diverticular, sigmoid polyp 1 
H Pylori Gastritis 6 
Hiatus Hernia and gastritis 1 
Hiatus Hernia and Vascular malformation 1 
Hiatus Hernia 3 
Hiatus Hernia and mild DD 2 
Hypothyroidism 1 
Inflammatory Bowel Disease 1 
Lung Cancer and Mild DD 2 
Myelodysplastic syndrome(MDS) and Distal Colonic Polyp 1 
MDS and Hiatus Hernia 1 
MDS and Severe DD 1 
MDS,  H Pylori Gastritis and Mild DD 1 
Menorrhalgia and HH 1 
Mild DD and Oesophageal ulcer 1 
Mild DD, Distal Colonic Polyp and HH 1 
Mild to Moderate Diverticular Disease(DD) 10 
Moderate DD and HH 2 
Myelodysplastic Syndrome(MDS) 3 
Normal GI tract and no cause identified.  6 
Oesophageal Stricture 1 
Oesophagitis 2 
Oesophagitis, Vascular telangiectasia 1 
On Warfarin for heart valve replacement and Mild Diverticular disease 1 
PCC, Barrett’s, Duodenal Polyp 1 
Postop Bleed and Severe DD 1 
Postop bleeding from Total knee Replacement 1 
Proximal Colonic Cancer 6 
Proximal Colonic Cancer and Mild DD 1 
Proximal Colonic Cancer and Gastric Ulcer 1 
Proximal Colonic Cancer and Gastritis 1 
Proximal Colonic Cancer, Gastritis AND Mild DD 1 
Proximal Colonic Cancer and H Pylori Gastritis and Mild DD 1 
Proximal Colonic Cancer and HP Gastritis 1 
Proximal Colonic Polyp 1 
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Proximal Colonic Polyp and Gastric Polyp 1 
Proximal Colonic Polyp and Gastritis 1 
Rheumatoid Arthritis and Mild DD 2 
Severe DD and Duodenal polyp 1 
Severe DD and HH and Barrett’s Oesophagus 1 
Severe Diverticular Disease 3 
Total 125 
 
Diverticular disease and gastritis were the commonest pathologies 
identified in the cohort, Table (5.4). 
Table 5.4:  Diagnosis groups in patients investigated for anaemia.  
Site Final Diagnosis 
No. of 
Patients 
% 
Lower GI Mild to moderate Diverticular Disease 44 35% 
Upper GI Gastritis 20 16% 
Upper GI Hiatus Hernia 19 15% 
Upper GI Helicobacter Pylori Gastritis 16 13% 
Systemic Systemic conditions(CRF, RA, Hypothyroid, recent postop bleed) 13 10% 
Lower GI Proximal Colonic Cancer 13 10% 
Lower GI Distal colonic polyp 9 7% 
Systemic Haematological Conditions 9 7% 
Lower GI Severe Diverticular Disease 8 6% 
Upper GI Barrett’s Oesophagus 7 6% 
Upper GI Oesophagitis 7 6% 
Upper GI Duodenitis 5 4% 
Lower GI Distal Colonic Cancer 4 3% 
Systemic Alcoholic Liver Disease 3 2% 
Upper GI Gastric Cancer 3 2% 
Upper GI Gastric Polyp 3 2% 
Upper GI Gastric Ulcer 3 2% 
Lower GI Proximal Colonic Polyp 3 2% 
Upper GI Duodenal Polyp 2 2% 
Lower GI Inflammatory Bowel Disease 2 2% 
Systemic Lung Cancer 2 2% 
Upper GI Gastric Vascular Malformations 2 2% 
Upper GI Cholangiocarcinoma 1 1% 
Upper GI Gastric Dysplasia 1 1% 
Systemic Gynaecological Bleeding 1 1% 
Upper GI Oesophageal Varices 1 1% 
Systemic Normal GI ( Nutritional iron deficiency) 6 5% 
 
As discussed in chapter 1 mild to moderate diverticular disease and 
uncomplicated hiatus hernia are not recognised as causes of  chronic 
occult blood loss from the GI tract [63, 77, 94-96].  Mild diverticular 
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disease and/or uncomplicated hiatus hernia was the only pathology 
identified in 15 patients.   
GI cancer was identified in 21 (16%) patients (13 proximal, 4 distal 
colonic cancer, 3 gastric cancers and 1 cholangiocarcinoma.) Non GI 
cancers were identified in 2 (2 lung cancers). One patient who was 
known to have bladder cancer that developed renal failure, and had new 
onset anaemia and hence was referred to the clinic to rule out GI cause 
of anaemia.  
Distribution of significant cause of anaemia based on site is listed in table 
5.5. Significant causes were defined as pathology that results in blood 
loss or decreased haemoglobin synthesis. Mild to moderate diverticular 
disease and non-complicated hiatus hernia were therefore excluded 
from causes of blood loss in the GI tract. For those with no GI cause of 
anaemia a site of systemic cause was recorded.  
Table5.5: Distribution of significant causes of anaemia.  
Site of main cause of anaemia No of Patients 
% of 
the 
total  
Patients 
with 
cancer 
Site specific 
cancer 
incidence 
Upper GI disease  50 40% 4 8% 
Systemic causes 38 30% 2 5% 
Colonic disease 17 14% 11 65% 
Upper GI and colonic disease  11 9% 6 55% 
Upper GI and systemic disease 6 5%   
Colonic and systemic disease 2 2% 2 100% 
Upper GI, colonic and systemic disease 1 1%   
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The upper GI tract was the commonest source of chronic blood loss 
(40%). However, the lower GI tract had the highest incidence of cancer as 
cause of chronic blood loss with 17 malignancies (13 proximal and 4 
distal colon cancers). In 16% of the patients more than one site was the 
cause of anaemia. It is important to note that colon cancer was identified 
in 55% of the patients with dual upper and lower GI pathology. In 30.4 % 
of the cohort no GI source of blood loss could be identified. 
Symptoms profile  
Following a structured interview using the symptoms proforma 
(Appendix 2), all patients’ symptoms were recorded and physical 
examination findings recorded.  
All 125 patients eligible for the study were analysed.  
Positive predictive values (PPV) of symptoms and past medical history for 
site of main cause of anaemia and cancer is summarised in tables 5.6 and 
5.7. 
 Heart burn and dyspepsia were the highest reported upper GI 
symptoms. In the presence of these symptoms, an upper GI cause of 
anaemia was found (PPV) in 69% and 66% respectively. However, when 
un-complicated hiatus hernia was removed, the PPV of heart burn and 
dyspepsia decreased to 48 and 50% respectively. It would have been 
expected in the presence of dyspepsia and anaemia that these patients 
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should have been referred urgently. In contrast to these expectations 
only 28% of dyspeptic patients with anaemia were referred urgently. 
Interestingly, the PPV of these two upper GI symptoms to distal colonic 
causes of anaemia was similar to significant upper GI causes (50%, 44% 
respectively). The PPV of these symptoms  for cancer was low (13%, 22%) 
confirming the lack of sensitivity and specificity of these symptoms for 
malignancy. Dysphagia was only reported in 9 (7%) patients. Only 22% of 
these patients were referred urgently.  The PPV of dysphagia for 
significant upper GI cause was 78%. As there was no patient with 
oesophageal cancer the PPV for Upper GI cancer was 0. 
None of the upper GI symptoms had a significant difference in their 
distribution with respect to cause of anaemia, type of cancer or route of 
referral (chi-square and fisher exact test where appropriate.)  
Change in bowel habit to loose motion or alternating loose motion and 
constipation was the commonest lower GI symptom reported. Upper GI 
causes of anaemia were more common in patients reporting change in 
bowel habit than patients with significant distal colonic pathology. In 
contrast increased frequency of bowel motion, although not common, 
was associated with a higher predictive value to distal colonic cause (PPV 
57%). Proximal colonic causes as expected had relatively low symptom 
prediction. None of the lower GI symptoms had a significant prediction 
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power to site of cause of anaemia or cancer. Constipation was higher in 
patients with upper GI cancer (22%, p=0.02 using Fisher exact test, 
however not significant when corrected for multiple tests using 
Bonferonni correction). 
Weight loss was reported in 32 (25%) of patients. Only 28% of patients 
with weight loss and anaemia have been referred through urgent routes. 
In patients reporting weight loss , anaemia was attributed to an upper GI 
cause, a significant upper GI disease and distal colonic disease in 50%, 
44% and 47% respectively. Only 13% of patients with weight loss had a 
proximal colonic cause of anaemia and none of the patients with weight 
loss had a significant distal colonic cause. With respect to all cancer, 19% 
of patients in this study reporting weight loss had cancer.  
Loss of appetite was reported in 20% and had a similar distribution to 
weight loss, except for a tendency to be have a lower PPV to distal 
colonic causes of anaemia. 
NSAID or aspirin use was reported in 53 (43%) patients. It was interesting 
to note that patients who were taking aspirin had a tendency to have a 
lower incidence of proximal colon diseases, cancer in general and lower 
GI cancer. 
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Table 5.6: Positive predictive values of presenting symptoms and past medical history with respect to type of referral and site of cause of anaemia. 
Symptom and PMH Total 
Urgent 
referrals 
(%) 
No cause 
identified 
(%) 
Upper GI 
cause 
(%) 
Significant 
upper GI 
cause (%) 
Proximal 
colonic 
cause 
(%) 
Distal 
colonic 
cause 
(%) 
Significant 
distal 
colonic 
cause (%) 
Systemic 
cause 
(%) 
Pre menopausal Women 3 1 (33%) 0 (0%) 3 (100%) 3 (100%) 0 (0%) 0 (0%) 0 (0%) 1 (33%) 
Heavy period 1 0 (0%) 0 (0%) 1 (100%) 1 (100%) 0 (0%) 1 (100%) 0 (0%) 0 (0%) 
Upper GI symptoms 
         
Heart burn or reflux 48 19 (40%) 8 (17%) 33 (69%) 23 (48%) 4 (8%) 24 (50%) 6 (13%) 11 (23%) 
Dyspepsia 32 9 (28%) 5 (16%) 21 (66%) 16 (50%) 4 (13%) 14 (44%) 5 (16%) 6 (19%) 
Upper abdominal pain 14 5 (36%) 2 (14%) 9 (64%) 7 (50%) 1 (7%) 5 (36%) 0 (0%) 2 (14%) 
Nausea 11 3 (27%) 3 (27%) 7 (64%) 4 (36%) 1 (9%) 4 (36%) 0 (0%) 1 (9%) 
Vomiting 7 4 (57%) 2 (29%) 4 (57%) 2 (29%) 0 (0%) 4 (57%) 2 (29%) 0 (0%) 
Dysphagia 9 2 (22%) 0 (0%) 8 (89%) 7 (78%) 1 (11%) 6 (67%) 1 (11%) 0 (0%) 
Previous history of gastric surgery 3 2 (67%) 0 (0%) 3 (100%) 3 (100%) 0 (0%) 2 (67%) 0 (0%) 0 (0%) 
Melena or Hematemesis 8 2 (25%) 1 (13%) 4 (50%) 4 (50%) 1 (13%) 5 (63%) 1 (13%) 2 (25%) 
Lower GI symptoms 
         
Small bowel surgery 2 0 (0%) 0 (0%) 1 (50%) 0 (0%) 1 (50%) 1 (50%) 0 (0%) 0 (0%) 
Blood in stool 17 6 (35%) 0 (0%) 14 (82%) 12 (71%) 1 (6%) 9 (53%) 2 (12%) 4 (24%) 
Change in bowel habits to loose motion 43 16 (37%) 7 (16%) 25 (58%) 19 (44%) 3 (7%) 24 (56%) 6 (14%) 6 (14%) 
Slime in stool 8 3 (38%) 1 (13%) 5 (63%) 3 (38%) 0 (0%) 5 (63%) 3 (38%) 2 (25%) 
Increased frequency of stool 7 3 (43%) 2 (29%) 2 (29%) 2 (29%) 1 (14%) 4 (57%) 2 (29%) 2 (29%) 
Constipation 9 1 (11%) 2 (22%) 6 (67%) 6 (67%) 0 (0%) 2 (22%) 1 (11%) 2 (22%) 
Central or lower abdominal pain 28 11 (39%) 5 (18%) 17 (61%) 14 (50%) 5 (18%) 13 (46%) 3 (11%) 5 (18%) 
History of Inflammatory bowel disease 4 2 (50%) 1 (25%) 2 (50%) 0 (0%) 0 (0%) 2 (50%) 1 (25%) 1 (25%) 
History of Polyps 3 1 (33%) 0 (0%) 2 (67%) 0 (0%) 1 (33%) 2 (67%) 1 (33%) 0 (0%) 
Family history of colon cancer 7 3 (43%) 1 (14%) 5 (71%) 2 (29%) 1 (14%) 4 (57%) 2 (29%) 1 (14%) 
Right iliac fossa (RIF) pain 8 3 (38%) 1 (13%) 4 (50%) 2 (25%) 0 (0%) 5 (63%) 1 (13%) 3 (38%) 
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Continue table (5.6): Positive predictive value of presenting symptoms and past medical history with respect to type of referral and site of cause of 
anaemia 
 
Symptom and PMH Total 
Urgent 
referrals 
(%) 
No cause 
identified 
(%) 
Upper GI 
cause 
(%) 
Significant 
upper GI 
cause (%) 
Proximal 
colonic 
cause 
(%) 
Distal 
colonic 
cause 
(%) 
Significant 
distal 
colonic 
cause (%) 
Systemic 
cause 
(%) 
Systemic Symptoms 
         
Weight loss 32 9 (28%) 6 (19%) 16 (50%) 14 (44%) 4 (13%) 15 (47%) 0 (0%) 7 (22%) 
Loss of appetite 25 8 (32%) 2 (8%) 14 (56%) 11 (44%) 5 (20%) 8 (32%) 1 (4%) 3 (12%) 
Brittle or abnormal nails 3 0 (0%) 0 (0%) 2 (67%) 2 (67%) 0 (0%) 2 (67%) 1 (33%) 0 (0%) 
Sore tongue 1 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (100%) 0 (0%) 0 (0%) 0 (0%) 
Night sweats 2 0 (0%) 0 (0%) 2 (100%) 2 (100%) 0 (0%) 1 (50%) 1 (50%) 0 (0%) 
Pruritus 2 0 (0%) 0 (0%) 1 (50%) 1 (50%) 0 (0%) 1 (50%) 1 (50%) 0 (0%) 
Joint pain 14 4 (29%) 0 (0%) 10 (71%) 9 (64%) 0 (0%) 10 (71%) 1 (7%) 3 (21%) 
Past Medical and Drug history 
         
PMH of RA 4 0 (0%) 1 (25%) 0 (0%) 0 (0%) 0 (0%) 3 (75%) 1 (25%) 2 (50%) 
PMH of Chronic renal failure 8 2 (25%) 2 (25%) 4 (50%) 3 (38%) 1 (13%) 2 (25%) 1 (13%) 5 (63%) 
On NSAIDS or Aspirin 53 16 (30%) 7 (13%) 34 (64%) 28 (53%) 3 (6%) 31 (58%) 3 (6%) 11 (21%) 
On Steroids 1 0 (0%) 0 (0%) 1 (100%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (100%) 
On Warfarin 9 1 (11%) 0 (0%) 6 (67%) 5 (56%) 3 (33%) 5 (56%) 1 (11%) 2 (22%) 
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Table 5.7: Positive predictive value of presenting symptoms and past medical history 
with respect to cancer.  
Symptom and PMH Cancer UG ca LG ca Non GI cancer 
Pre menopausal Women 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
Heavy period 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
Upper GI symptoms 
    
Heart burn or reflux 6 (13%) 0 (0%) 5 (10%) 1 (2%) 
Dyspepsia 7 (22%) 2 (6%) 5 (16%) 0 (0%) 
Upper abdominal pain 2 (14%) 1 (7%) 1 (7%) 0 (0%) 
Nausea 1 (9%) 0 (0%) 1 (9%) 0 (0%) 
Vomiting 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
Dysphagia 1 (11%) 0 (0%) 1 (11%) 0 (0%) 
Previous gastric surgery 1 (33%) 1 (33%) 0 (0%) 0 (0%) 
Melena or Hematemesis 1 (13%) 0 (0%) 1 (13%) 0 (0%) 
Lower GI symptoms 
    
small bowel surgery 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
Blood in stool 3 (18%) 1 (6%) 2 (12%) 0 (0%) 
Change in bowel habits to loose 
motions 
7 (16%) 3 (7%) 4 (9%) 0 (0%) 
Slime in stool 1 (13%) 0 (0%) 1 (13%) 0 (0%) 
Increased frequency of stool 1 (14%) 0 (0%) 1 (14%) 0 (0%) 
Constipation 3 (33%) 2 (22%) 0 (0%) 1 (11%) 
Abdominal pain (Central or lower) 7 (25%) 0 (0%) 6 (21%) 1 (4%) 
History of Inflammatory bowel 
disease 
0 (0%) 0 (0%) 0 (0%) 0 (0%) 
History of Polyps 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
Family history of colon cancer 1 (14%) 0 (0%) 1 (14%) 0 (0%) 
Right Iliac Fossa (RIF) Pain 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
Systemic Symptoms 
    
Weight loss 6 (19%) 2 (6%) 4 (13%) 0 (0%) 
Loss of appetite 5 (20%) 0 (0%) 0 (0%) 0 (0%) 
Brittle or abnormal nails 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
Sore tongue 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
Night Sweats 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
Pruritus 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
Joint pain 2 (14%) 2 (14%) 0 (0%) 0 (0%) 
Past Medical and Drug history 
    
PMH of RA 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
PMH of Chronic Renal Failure 2 (25%) 0 (0%) 2 (25%) 0 (0%) 
On NSAIDS or Aspirin 5 (9%) 1 (2%) 3 (6%) 1 (2%) 
On Steroids 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
On Warfarin 2 (22%) 0 (0%) 2 (22%) 0 (0%) 
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Blood indices profile 
All 125 patients studied had their full blood count assessed. The mean 
haemoglobin (Hb) of the cohort studied was 106 g/l ( SD 15.2g/l). The 
average Hb was significantly lower in females (p=0.001) as well as patients 
with cancer (p=0.0001) (significant level p value after Bonferroni correction 
is 0.002)  (Table 5.8).  
Females had a lower Hb, HCT, MCV MCH, MCHC and ferritin as compared to 
men. There was no difference in RBC, RDW, serum iron levels, vitamin B12 or 
Folate. 
Patients with cancer had a significantly lower mean Hb, HCT, and MCV. There 
was no significant difference between those with cancer and those without 
with regard to the serum iron, ferritin, vitamin B12 and Folate (Table 5.8).  
When the blood indices were compared with respect to the site of main 
cause of anaemia, there was a tendency for patients with lower GI disease as 
cause of anaemia to have lower Hb, low MCV and a low MCH. This tendency 
did not reach statistical significance (Table 5.9).   
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Table 5.8: Mean and standard deviation of blood indices with respect to gender and cancer  
Sex 
No of 
Patients 
Mean of blood index(SD) 
Hb RBC HCT MCV MCH MCHC RDW Iron ferritin B12 FA 
Total 125 106.1(15.2) 4.1(0.7) 33.8(4) 84(9.9) 26.4(4.2) 313.2(20.8) 16.3(2.6) 10.1(9.2) 71.7(84.4) 389.5(230) 9.2(8.2) 
Male 64 110.3 (15.2) 4.1 (0.8) 34.6 (4.2) 86 (10.3) 27.2 (4.3) 317.3 (15.6) 15.9 (2.1) 11.5 (10.4) 83.8 (78.5) 356(214.8) 10 (10.6) 
Female 61 101.6 (14) 4 (0.5) 32.8 (3.5) 82 (9.2) 25.4 (4.1) 309 (24.6) 16.6 (3) 8.7 (7.8) 60.6 (88.8) 
417 
(242.3) 
8.3 (4.9) 
p value 
 
0.001 0.37 0.01 0.026 0.016 0.026 0.14 0.08* 0.02* 0.07* 0.7 
Cancer 23 94.1 (17.5) 4 (0.5) 31 (4.4) 78.1 (9.9) 23.7 (4.5) 302 (21.5) 17.2 (2.6) 10.1 (12.4) 54.7 (77.3) 
454 
(272.8) 
9.6 (5.8) 
Non 
Cancer 
102 108.8 (13.3) 4.1 (0.7) 34.4 (3.6) 85.4 (9.5) 26.9 (4) 315.8 (19.9) 16 (2.6) 10.1 (8.6) 74.8 (85.6) 
378 
(221.4) 
9.1 (8.6) 
p value 
 
0.0001* 0.46* 0.0004* 0.001* 0.004* 0.004* 0.019* 0.4 0.15 0.4 0.7 
T test was used to compare means. *Mann-Whitney U test was used if the data was not normally distributed.   
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Table 5.9 : Mean and standard deviation of blood indices with respect to main site of cause of anaemia 
Site of Cause of Anaemia 
No of 
Patients 
Mean of blood index(SD) 
Hb RBC HCT MCV MCH MCHC RDW Iron Ferritin B12 FA 
Upper GI disease 50 
106.9 
(15.3) 
4.2 (0.7) 34.1 (4.1) 
83.1 
(10.9) 
26.2 (4.8) 
313.1 
(27.2) 
16.4 (2.7) 9.7 (8.4) 
56.5 
(64.6) 
397.5 
(205.4) 
9.3 (4.8) 
Systemic causes 38 
108.6 
(13.3) 
4 (0.6) 34.1 (3.8) 87 (8.5) 27.7 (3.3) 
317.9 
(12.7) 
15.7 (2.1) 9.5 (6.2) 95.8 (98) 
338.7 
(219.8) 
7.7 (6.1) 
Colonic disease 17 
98.6 
(17.6) 
4.1 (0.5) 32 (4.5) 78.9 (8.3) 24.3 (3.6) 
306.7 
(16.1) 
17.2 (2.7) 7.2 (6) 
28.4 
(48.1) 
303.9 
(144.4) 
15.2 
(19.7) 
Upper GI and colonic disease 11 
101.4 
(16.1) 
4.1 (0.4) 33.1 (3.6) 
81.5 
(10.5) 
25 (4.6) 304.7 (18) 17.2 (3.9) 
17.6 
(21.7) 
92.1 
(137.6) 
640.9 
(387.7) 
7.4 (4.6) 
Upper GI and systemic 
disease 
6 
116.8 
(10.6) 
4.4 (1.2) 35.3 (3.5) 89.3 (6.8) 27.3 (4.8) 
325.4 
(3.1) 
14.9 (1.3) 13 (5) 100.8 (79) 
341.5 
(113.3) 
8.2 (2.1) 
Colonic and systemic disease 2 
103.5 
(6.4) 
3.5 (0.2) 32.8 (2.1) 93.3 (1.3) 29.4 (0.4) 315 (0) 14.5 (1.7) 10.5 (2.1) 
102.5 
(16.3) 
552 
(172.5) 
8.1 (1.5) 
Upper GI, colonic and 
systemic disease 
1 90 3.8 31.5 83.6 23.9 286 15.9 3 10 479 7.5 
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Amongst those patients with cancer, the MCV and MCH were lower in 
patients with cancer in the GI tract compared with those with non GI tract 
cancers. This did not reach statistical significance (Table 5.10). 
When the anaemia thresholds for referral guidelines were applied to the 
cohort it was apparent that highest sensitivity across all different criteria was 
for a colonic cause for anaemia (Table 5.11).  
Discussion 
In this section a cohort of patients referred by their GPs with unexplained 
anaemia underwent an upper and/or lower GI investigation. A cause was 
identified in 95% of patients. 6 patients had iron deficiency responding to 
iron and resolved completely with no further pathology identified at one 
year of follow up. High compliance with invasive investigations was 
observed, although compliance with FOB testing was poor (25%). 
This study confirmed what was previously reported in literature[59, 60, 62, 
63, 76, 97-106] that upper GI causes of occult blood loss are the commonest 
(40%), followed by systemic (30%) and lower GI causes (14%). Cancer 
incidence was highest in the lower GI tract with 65% of the patients with a 
lower GI cause of anaemia having colon cancer followed by patients who had  
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Table 5.10: Mean and standard deviation of blood indices with respect to type of cancer 
Final Diagnosis 
No OF 
patients 
Mean of blood index(SD) 
Hgb RBC HCT MCV MCH MCHC RDW Iron ferritin B12 FA 
Proximal colonic cancer 13 
93.7 
(16.3) 
3.9 (0.5) 31 (4.2) 79.1 (10.8) 24 (4.6) 
301.1 
(16.7) 
16.8 (2.7) 12.8 (15.8) 33.8 (55.5) 538.3 (300) 8.8 (4.8) 
Distal colonic cancer 4 93 (17.5) 4.3 (0.4) 31 (4.7) 72.5 (7.9) 21.8 (3.5) 
299.8 
(17.5) 
18.3 (1.6) 8.3 (7.8) 20.5 (20.5) 216.5 (62) 14.6 (13.3) 
Gastric Cancer 3 93.7 (12) 4 (0.7) 30.8 (2.6) 77.8 (8.6) 24 (5.9) 
305.3 
(39.9) 
18.1 (4.3) 5 (3) 95 (120.8) 445.3 (190) 9.9 (4.8) 
Lung Cancer 2 
115.5 
(19.1) 
4.1 (0.2) 35.4 (5.9) 86.6 (10.8) 28.3 (3.5) 327 (0) 16.2 (1.9) 7  190 190  5.4 
Cholangiocarcinoma 1 62 3.3 23.5 71 18.7 264 17.7 
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Table 5.11: Distribution of different referral guidelines thresholds and main site of cause of anaemia.  
Site of cause of anaemia Total 
Number of Patients meeting referral criteria( %) 
Anaemia Microcytosis BSG DoH IDA DoH IDA 
Upper GI disease 50 47 (94%) 17 (34%) 20 (40%) 14 (28%) 22 (44%) 9 (18%) 
Systemic causes 38 35 (92%) 11 (29%) 7 (18%) 14 (37%) 12 (32%) 2 (5%) 
Colonic disease 17 17 (100%) 10 (59%) 9 (53%) 9 (53%) 11 (65%) 7 (41%) 
Upper GI and colonic disease  11 11 (100%) 4 (36%) 5 (45%) 6 (55%) 6 (55%) 3 (27%) 
Upper GI and systemic disease 6 6 (100%) 0 (0%) 1 (17%) 1 (17%) 1 (17%) 0 (0%) 
Colonic and systemic disease 2 2 (100%) 0 (0%) 0 (0%) 1 (50%) 0 (0%) 0 (0%) 
Upper GI, colonic and systemic disease 1 1 (100%) 0 (0%) 1 (100%) 1 (100%) 1 (100%) 0 (0%) 
All cancers 23 23 (100%) 16 (70%) 19 (83%) 16 (70%) 19 (83%) 13 (57%) 
Cancers of the Upper GI tract 4 4 (100%) 3 (75%) 3 (75%) 3 (75%) 3 (75%) 3 (75%) 
Cancers of the colon 17 17 (100%) 11 (65%) 14 (82%) 12 (71%) 14 (82%) 10 (59%) 
Non GI cancers 2 2 (100%) 2 (100%) 2 (100%) 1 (50%) 2 (100%) 0 (0%) 
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dual upper and lower GI pathologies, with 55% having colon cancer in 
addition to a benign upper GI cause of anaemia.  
With regards to referral categories it was evident that compliance with 
national guidelines was poor as many patients with alarm symptoms and 
anaemia were not referred urgently. Only 28% of dyspeptic patients who had 
anaemia were referred via an urgent pathway and only 22% of patients with 
dysphagia had an urgent review requested.  
The commonest upper GI symptoms of heart burn and dyspepsia had an 
associated significant cause of anaemia in 48% and 50% of patients 
respectively. The incidence of heart burn and reflux have been reported to 
be 10% to 48% in the general population[30].  Dysphagia was only reported 
in 9 (7%) of the studied cohort. None of the upper GI symptoms had a 
significant difference in their distribution with respect to cause of anaemia, 
type of cancer or route of referral. Dyspepsia is nonspecific to organic 
conditions of the upper GI tract[107]. However, when detailed scoring of 
symptoms has been performed, it is able to identify patients at high risk of 
having significant pathology in the upper GI tract[108]. In contrast, the yield 
of cancer diagnosis from referrals of patients with alarm symptoms of upper 
GI tract has been low, with incidence ranging from 4% to 15% [74, 109].  
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The value of these symptoms in our anaemic population was not confirmed 
on univariate analysis.  
High risk symptoms such as dysphagia and weight loss have been included as 
individual factors or as part of scoring systems to identify significant upper GI 
disease and cancer with some success, with an odds ratios of 2 for upper GI 
disease and 6 for cancer [31, 74, 110].  
Change in bowel habit to loose motion or alternating loose motion and 
constipation were the commonest lower GI symptoms reported in this 
cohort. None of the lower GI symptoms had a significant relationship with a 
site of cause of anaemia except for constipation which has a tendency to be 
higher in patients with upper GI cancer (22%).  
Loose motion and blood in the stool in the absence of perianal symptoms are 
high risk factors for significant lower GI disease with high predictive value for 
distal colonic cancer, colitis and large polyps [18, 27, 111, 112]. However 
their association with proximal colon cancer is poor. Loose motion has been 
included in a risk score by Fijten et al to predict colorectal cancer in general 
but does not differentiate if it is proximal or distal [12]. Majumdar et al 
demonstrated a 1.96 odds ratio of distal cancer when cluster symptoms 
(included loose motions) existed [11]. However, even in the presence of 
anaemia loose motions does not help predict PCC in the literature.  
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Weight loss was reported in 32 (25%) patients. The majority of these patients 
had a significant upper GI cause of anaemia. Only 19% of the patients with 
cancer in our cohort reported weight loss.  
Blood profiles showed patterns that were correlated with causes of anaemia; 
patients with cancer had significantly lower haemoglobin and other blood 
indices compared with patients without cancer. The upper GI causes group 
had a tendency to have a higher MCV, MCH and lower RDW as compared 
with the lower GI causes group. This is explained by the longer silent phase 
of lower GI cancers and the potential of re absorption of heme from the 
upper GI tract slowing the progression of iron deficiency.   
Iron studies, as well as B12 and folate, did not show significant differences 
between site causes of anaemia. However, patients with cancer did show a 
lower ferritin level compared with those without. This was even more 
pronounced in colonic cancers as compared to upper GI cancers.  
Systemic causes of anaemia had a higher MCV, and MCHC with a lower RDW, 
MCH, and HCT.  This pattern of anaemia reflects the common mechanism by 
which non-GI causes develop anaemia [49, 113, 114]. Erythropoiesis is 
deprived of iron as it is sequestrated in chronic inflammation response[49]. 
This iron deprived erythropoiesis commonly presents as normocytic (normal 
MCV), normochromic (normal MCHC)[48, 115] anaemia. The relatively 
normal RDW is likely due the slow development of anaemia in these patients 
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and chronicity of the condition which results in a homogenous population of 
red blood cells[116].  
When assessing the pattern from GI causes of anaemia; it is evident that 
there is a pattern differentiating upper from lower GI causes.  
In our univariate analysis colonic causes of anaemia had a lower MCV, MCH, 
MCHC and a higher RDW compared with upper GI causes. This is similar to 
the demonstrated pattern in the study of anaemia profiles in GI cancers 
(chapter 4).  
It is evident from this study that the use of individual symptoms will not be 
successful in predicting the likely cause of anaemia or site of blood loss. In 
contrast, blood profile index, e.g. MCV or RDW, can allow a broader 
stratification of likely site of blood loss. Due to this the referral guidelines 
yield had a poor sensitivity and specificity for predicting site of cause of 
anaemia or for predicting cancer. The only measurable improvement in 
predicting cancer risk from referral guidelines[17, 24] , dyspepsia score[74], 
colorectal cancer risk scores [11, 12, 16] was achieved when combination of 
high risk symptoms and blood findings was performed. It is thus important to 
explore the predictive power of combining symptoms and blood indices to 
identify the site of blood loss and cancer risk.   
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Chapter 6 
Development of streamlining tool for 
investigation of patients with anaemia 
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Development of streamlining tool for investigation 
of patients with anaemia 
 
Abstract  
DOH and BSG guidelines use symptoms and the presence of anaemia to 
classify patients at high risk of having serious GI pathology or cancer. 
The yield of significant disease from urgent referrals is poor using these 
criteria due to the poor specificity.  
In previous chapters of this it has been identified that GI symptoms are 
common and that they are not specific in identifying serious GI pathology 
causing anaemia. In contrast blood profiles have demonstrated a trend in 
identifying upper and lower GI pathology group.  
This study aims to use the combination of symptoms and blood profiles to 
predict the likely site of cause of IDA and to develop a tool that could aid 
clinicians to quantify risk of site of blood loss and therefore guide in 
streamlining investigations.  
A multistep logistic regression method was applied. Prediction scores of 
symptoms to predict likelihood of upper, lower GI and systemic causes of 
IDA was generated. Then the same was performed for blood profiles. Both 
scores were then combined to generate an overall score that combines 
symptoms and blood profiles in one tool. This score was then refined by 
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stepwise logistic regression analysis to reduce factors to generate a scoring 
tool that could be applied easily in the clinical setting.  
Although upper GI symptoms have a positive correlation with the presence 
of upper GI pathology this did not reach statistical significance. ROC analysis 
demonstrated a good discriminatory power of the upper GI symptoms model 
with AUC of 0.69 (SE 0.05). The lower GI symptom regression model 
identified male gender and loss of appetite as positive predictors and young 
age, weight loss and NSAID use as negative predictors of lower GI pathology. 
The model had very good discriminatory power with AUC of 0.81 (SE 0.05). 
Blood indices regression models identified a high MCH as a predictor of 
upper GI pathology in females. In contrast to this, no combination of indices 
demonstrated an independent predictor of lower GI pathology. The upper GI 
blood model had AUC 0.77 (SE 0.05) and the lower GI blood model had AUC 
0.77 (SE 0.06).  
The combined scores model demonstrates significant prediction of the lower 
GI symptom and blood scores to a lower GI pathology. The discriminatory 
power was excellent with AUC of 0.91(SE 0.05). The combined upper GI 
model had an AUC of 0.77(SE0.05). 
Using stepwise logistic regression analysis a clinical risk scoring tool was 
developed. The discriminatory power of the scores was good for upper GI 
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(AUC 0.72), very good for lower GI (AUC 0.86) and good for non-GI causes 
(AUC 0.69).  
The clinical scoring tool mean scores were significantly higher for patients 
with pathology or cancer at the respective GI sites. The tool also identified 
patients with dual site pathology.  
The scoring tool aided in predicting the likely site of pathology in patients 
referred with unexplained IDA, therefore aiding in streamlining patients to 
the appropriate investigation.  
 
Introduction  
The previous section assessed the profile of symptoms and blood indices in 
patients investigated for unexplained iron deficiency anaemia.  
Analysis of each presenting symptom and its prediction of cause of anaemia 
failed to identify a strong predictor of cause of anaemia. This is due to the 
lack of specificity and high prevalence of these symptoms in the referred 
population. GI symptoms have been predictive of GI pathology [74, 80, 108], 
however the pathologies that cause chronic blood loss might not necessarily 
have pronounced symptoms.   
Blood indices have demonstrate a trend to differentiate upper and lower GI 
pathology ( chapter 4, chapter 5).  
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DOH and BSG guidelines use symptoms and anaemia broadly to classify 
patients at high risk of having cancer or GI pathology as a source of chronic 
blood loss.  
This study assesses the use of a combination of detailed symptoms profile 
and blood indices in the prediction of the site of GI pathology, and to use 
that to develop a clinical tool that aids in classification of risk of site of 
pathology in unexplained IDA.   
Methods 
125 patients investigated for unexplained anaemia symptoms and blood 
indices profiles were analysed.  
Univariate analysis of symptoms and blood profile indices in predicting site 
of blood loss was conducted in the previous chapter. Using that as a guide, 
multivariate analysis in the form of logistic regression was used to generate 
the prediction models. The investigation pathway of each patients follows an 
upper or lower GI assessment at first. Thus to reflect the clinical pathway of 
investigation, this study aimed to generate a tool that predicts the 
probability of cause of anaemia in one or more of three sites: upper, lower 
gastro-intestinal (GI) or non-GI causes of anaemia. It is also possible that a 
patient could have more than one site that could be contributing to the 
anaemia or have a significant pathology accounting for their symptoms. Due 
to this it would not be appropriate to use multivariate analysis to predict 
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three sites in one model (i.e. discriminate analysis). Hence logistic regression 
analysis was used to generate models using symptoms and blood indices to 
predict probability of each site (upper, lower or non-GI) separately [117].  
The prediction score development followed a multistep process over 3 step 
processes: (see flow chart of model development in Appendix 3 and 4)  
Step 1: Symptoms prediction of each site of pathology 
Symptoms from each site of potential blood loss were entered in a 
logistic regression analysis to study the association of symptoms and 
the respective site. Constitutional symptoms such as loss of appetite 
and weight loss and use of NSAIDs or steroids are known to be 
associated with pathology at all three sites. They were included with 
respective site specific symptoms in the regression analysis for each 
site model.  
In attempt to create a simpler model that is user friendly (with fewer 
symptoms), regression analysis with stepwise selection protocol was 
used. A factor was selected if the p value of the regression coefficient 
was lesser or equal to 0.2.  
The regression coefficients were rounded to the nearest single 
decimal and then used to generate the weight of main symptoms.  A 
risk score for each site based on symptoms was then generated.  
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Step 2: Blood Indices and prediction of each site of pathology 
In a similar manner to symptoms, blood indices of interest were also 
entered in logistic regression to generate a score to predict the main 
site of possible cause of anaemia. 
Using regression analysis with stepwise selection protocol a reduced 
prediction model to lower the number of factors was constructed.  A 
factor was selected if the p value of the regression coefficient was 
lesser or equal to 0.2. The regression coefficients were rounded to the 
nearest single decimal and then used to generate the weight of main 
symptoms.  A score was then generated for blood indices for each site.  
Step 3: Combination scoring model using the symptom and blood models 
from steps 1 and 2  
Both scores were combined in a logistic regression model to produce a 
probability prediction model for each site.  Each patient then had a 
probability of having a condition causing anaemia at each site 
generated.  
This stepwise approach was chosen to reflect current clinical practice. In a 
clinical setting the clinician would take history and examine a patient then 
based on their findings the risk of a cause of anaemia is estimated and the 
method of investigation determined. That risk was translated in an objective 
manner by using logistic regression to predict cause of anaemia using site 
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specific symptoms at first.  Using blood indices to predict cause of anaemia 
was generated independent of symptoms. Symptoms and blood indices 
findings combined interaction is then assessed in a logistic regression model 
in the form of the combined model. This multistep approach will also adjust 
for the potential difference in type of correlation of factors and dependant 
outcome. It was assumed that all factor correlations with the outcome are a 
linear one.  By separating symptoms and blood indices regression models, 
we have adjusted (normalised, or linearised) for the non-nonlinear 
relationship at each model. The final combined model will use linear 
independent factors (a symptom score and blood index score).    
The final model reliability was assessed using the Receiver Operator 
Characteristic Curve (ROC) and Area Under Curve (AUC)[117].  
Score cut off points for each site were selected to achieve a minimum 
sensitivity of 80%. When a score is above the chosen threshold it indicated 
the need for investigating the site accordingly.  
Sensitivities, specificities and positive predictive values to cancer of the 
upper and lower GI tracts were also calculated. 
Statistical analysis was conducted using t-test, paired t test, Mann-Whitney U 
test, chi-square test, Fisher exact test, McNemar test (paired chi-square test 
to measure disagreement) where appropriate.  
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Results 
Step 1: Prediction of site of pathology using symptoms and a modelling of 
site symptom score:  
Upper GI pathology symptom model: 
Symptoms that are specific to upper GI conditions and systemic symptoms 
associated with upper GI causes were entered in the logistic regression 
analysis (Table 6.1). 
There was no significant relationship between upper GI symptoms, patient 
characteristics or demographics and upper GI causes of anaemia except for 
male gender.  In the presence of anaemia, symptoms such as dyspepsia, 
dysphagia, nausea and use of NSAIDS, which are known to be a risk of 
presence of pathology in the upper GI tract, have been confirmed to be 
positively correlated with presence of a significant cause of anaemia in UGI 
tract. In contrast, older patients, male sex, reflux and vomiting have a trend 
to predict the absence of a significant upper GI cause of blood loss.    
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Table 6.1 Logistic regression of symptoms and upper GI causes of anaemia 
Variable 
Regression 
Coefficient 
Standard 
Error 
p value 
Intercept 1.70489 1.316018 0.195151 
Age -1.65E-02 1.77E-02 0.351047 
Male gender -0.86785 0.410032 0.034298 
Heart burn or reflux -0.16156 0.470437 0.731286 
Dyspepsia 0.328875 0.559869 0.556926 
Epigastric or RUQ Pain -6.86E-02 0.770992 0.929098 
Nausea 0.39752 0.944819 0.673948 
Vomiting -0.98507 1.076923 0.360346 
Dysphagia 1.168429 0.904587 0.196471 
Previous gastric surgery 16.35293 3093.51 0.995782 
Melena or Hematemesis 6.92E-02 0.798944 0.930958 
Weight loss -0.29485 0.521854 0.572069 
Loss of appetite  -0.2613 0.572826 0.648277 
NSAIDS or Aspirin  0.327141 0.410104 0.425043 
Steroids -17.828 5439.527 0.997385 
Warfarin 0.403977 0.823349 0.623673 
 
Figure 6.1 : Receiver Operating  Characteristic Curve (ROC) for upper GI symtpoms and 
blood score prediction model 
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The upper GI cause probability model based on symptoms was generated 
using all factors entered in the logistic regression model. This had a 
discriminatory power that was good with an area under receiver operating 
characteristic curve (AUC) of 0.69(SE 0.05)( Figure 6.1).   
Lower GI pathology symptom model: 
Table (6.2) lists the factors entered in lower GI cause prediction model.  
Older age, absence of weight loss and use of NSAIDS were the only 
significant predictors of lower GI pathology. 
In contrast to what has been reported in literature, change in bowel habit to 
loose motions or increased frequency was not a positive predictor of 
significant lower bowel pathology. However loss of appetite and male 
gender had a tendency to predict a significant pathology.    
As has been noted in univariate analysis in earlier chapter, NSAID use had a 
trend to protect from significant lower GI pathology.  
The model generated for lower GI pathology had a very good discriminatory 
power with AUC of 0.81(SE 0.05) (Figure 6.2) 
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Table 6.2 Logistic regression of symptoms and Lower GI causes of anaemia 
Variable 
Regression 
Coefficient 
Standard 
Error 
p value 
Intercept -5.37213 1.897461 0.004637 
Age 6.83E-02 2.61E-02 0.008783 
Male gender 0.145492 0.514794 0.777467 
Blood in stool -0.57284 0.843355 0.496988 
Change in bowel habits to loose 
motion or alternating  
-0.81231 0.634027 0.200126 
Slime in stool  1.028066 1.031938 0.31913 
Increased frequency of stool -0.34665 1.214421 0.775306 
Constipation  -0.97988 1.265433 0.438727 
Abdominal pain 0.890447 0.657207 0.175451 
Inflammatory Bowel Disease -2.57583 1.630615 0.114183 
History of colonic polyps 1.316398 1.819618 0.469405 
Family history of colorectal cancer 0.964861 1.233193 0.433974 
RIF pain -8.24E-02 1.395314 0.952926 
Weight loss -2.13843 0.896713 0.017091 
Loss of appetite  1.546345 0.904979 0.087505 
NSAIDS or Aspirin  -1.72756 0.578502 0.002824 
Steroids -18.761 3299.24 0.995463 
Warfarin 0.638578 0.952169 0.50244 
 
 
 
Figure 6.2: Receiver Operating  Characteristic Curve (ROC)for Lower GI Symtpoms and 
Blood Score prediction model 
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Non GI causes of anaemia prediction model: 
None of the systemic symptoms had a significant prediction of non-GI 
pathology. Being female was a significant independent predictor of non-GI 
causes (Table 6.3). 
The model for non-GI causes of anaemia had a good discriminatory power 
with an AUC of 0.75(SE 0.05)( Figure 6.3). 
 
Table 6.3 Logistic regression of symptoms and non-GI causes of anaemia 
Variable 
Regression 
Coefficient 
Standard 
Error 
p value 
Intercept 0.22679 1.32046 0.863634 
Age -2.28E-02 1.86E-02 0.22154 
Male gender 1.065562 0.449875 0.017857 
Weight loss 0.817102 0.558968 0.143795 
Loss of appetite -0.56341 0.66207 0.394782 
Abnormal nails 18.48434 5439.527 0.997289 
Sore tongue -14.2686 5439.527 0.997907 
Night sweats  -34.5622 6624.828 0.995837 
Pruritus -16.6919 3727.765 0.996427 
Joint pain -0.4118 0.741615 0.578706 
Rheumatoid Arthritis 2.602973 1.74179 0.135065 
Chronic Renal Failure 0.914686 0.90113 0.310085 
NSAIDS or Aspirin 0.495769 0.448692 0.269195 
Steroids 20.4224 5439.527 0.997004 
Warfarin -1.88312 1.211445 0.120079 
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Figure 6.3: Receiver Operating  Characteristic Curve (ROC) for Non- GI symtpoms and 
blood score prediction model 
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High serum iron and low ferritin were associated with a tendency to find an 
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Table 6.4 Logistic regression of blood indices and iron studies and upper GI causes of 
anaemia 
Variable 
Regression 
Coefficient 
Standard 
Error 
p value 
Intercept 35.02379 50.92329 0.491594 
AGE -1.12E-02 2.36E-02 0.635342 
Sex -1.77598 0.570358 0.001847 
Hb -0.69997 0.494078 0.156564 
RBC 0.364344 2.787449 0.896006 
HCT 2.296068 1.705369 0.178181 
MCV -1.299 0.664429 0.050576 
MCH 4.294783 1.886189 0.022788 
MCHC -0.13582 0.166095 0.413524 
RDW 5.21E-03 0.117015 0.964458 
Iron 4.13E-02 3.26E-02 0.204449 
Ferritin -2.73E-03 3.01E-03 0.363573 
 
None of the indices were a significant predictor of lower GI pathology.  
However, relatively high haemoglobin and low haematocrit had a tendency 
to predict lower GI causes (Table 6.5). 
Based on logistic regression model the discriminatory power was good with 
AUC of 0.77(SE 0.06) (Figure 6.2). 
Table 6.5 Logistic regression of blood indices and iron studies and lower GI causes of 
anaemia 
Variable 
Regression 
Coefficient 
Standard 
Error 
p value 
Intercept 88.08009 65.55109 0.17905 
Age 8.53E-03 2.82E-02 0.76246 
Sex 0.349876 0.627678 0.577246 
Hb 1.384272 0.715906 0.053163 
RBC -2.30523 4.515726 0.609709 
HCT -4.15305 2.416626 0.0857 
MCV 0.789414 0.78913 0.317137 
MCH -2.85955 2.2342 0.200581 
MCHC -0.25759 0.213908 0.228507 
RDW 0.128121 0.136513 0.347975 
Iron 3.54E-02 3.11E-02 0.255083 
Ferritin 6.69E-04 3.51E-03 0.849007 
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Being male with high MCV and low MCH was significantly associated with 
non-GI causes of anaemia.(Table 6.6). The AUC of the non-GI model was 
0.78(SE 0.05)( Figure 6.3) 
The discriminatory powers of all prediction sub scores are listed in table 6.7 
 
Table 6.6 Logistic regression of Blood indices and iron studies and non-GI causes of 
anaemia 
Variable 
Regression 
Coefficient 
Standard 
Error 
p value 
Intercept -73.24 59.46578 0.218086 
Age -0.0211 2.40E-02 0.378007 
Sex 1.484863 0.542451 0.006194 
Hb 0.417138 0.51347 0.416568 
RBC 1.661527 3.308955 0.615576 
HCT -1.62495 1.792964 0.364781 
MCV 1.468567 0.739989 0.047191 
MCH -4.32203 2.060449 0.035939 
MCHC 0.225358 0.187308 0.228922 
RDW -0.14945 0.134587 0.266808 
Iron -0.02066 3.18E-02 0.515958 
Ferritin 0.00342 2.99E-03 0.252775 
 
Table 6.7 Discriminatory powers as assessed by Area Under ROC Curve (AUC) of 
symptoms and blood score models for prediction of respective sites.   
Prediction Model AUC SE 
Upper GI symptom  score 0.686533 0.047 
Upper GI blood score 0.765278 0.04824 
Lower GI symptom  score 0.816232 0.049423 
Lower GI blood score 0.77332 0.064244 
Non- GI symptom  score 0.746045 0.04726 
Non-GI Blood score 0.783285 0.05122 
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Step 3: Combination scoring model using the symptom and blood models 
from steps 1 and 2 to predict probability of cause of anaemia at each site.   
Each patient has a probability of an upper GI, lower GI, and non-GI cause of 
anaemia. Because each site has its own independent symptom and blood 
profile, a risk score for each site is needed by combining the respective site 
symptom and blood profile score models in a logistic regression model. 
(Tables 6.8, 6.9, 6.10) 
 
Table 6.8 Logistic regression of upper GI symptom and blood scores models to develop 
the upper GI cause probability prediction model.  
Variable 
Regression 
Coefficient 
Standard Error p value 
Intercept -3.28263 0.963322 0.000655 
Upper GI symptom  Score 2.256121 1.631184 0.166629 
Upper GI Blood Score 4.182976 1.200895 0.000495 
 
Table 6.9 Logistic regression of lower GI symptom and blood scores models to develop 
the lower GI cause probability prediction model.  
Variable 
Regression 
Coefficient 
Standard Error p value 
Intercept -5.0211 0.980781 0 
Lower GI symptom  Score 7.227287 1.864614 0.000106 
Lower GI Blood Score 6.473686 1.807623 0.000342 
 
Table 6.10 Logistic regression of non-GI symptom and blood scores models to develop 
the non-GI cause probability prediction model. 
Variable 
Regression 
Coefficient 
Standard Error p value 
Intercept -3.43909 0.692354 0.000001 
Non- GI symptom  Score 3.702015 1.368322 0.00682 
Non-GI Blood Score 3.754554 1.256895 0.002816 
 
 
111 
 
 
1
1
1
 
Except for upper GI symptoms, it is evident that site symptoms and blood 
score components are significant predictors of significant causes of anaemia 
at relevant GI sites.   
The ROC curves for the full models for each site are presented in figures 6.4, 
6.5 and 6.6.  
Figure 6.4: Receiver Operating  Characteristic Curve (ROC) for  the upper GI cause 
probability model 
 
Figure6.5: Receiver Operating  Characteristic Curve (ROC) for  the lower GI cause 
probability model 
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Figure 6.6: Receiver Operating  Characteristic Curve (ROC) for  the Non-GI cause 
probability model 
 
Lower GI site cause probability model had the highest discriminatory power 
with an AUC of 0.91(SE 0.05) followed by non GI cause probability model 
with an AUC of 0.82(SE 0.05) and upper GI with AUC of 0.77(SE 0.05) (Table 
6.11).  
 
Table 6.11 Discriminatory powers as assessed by Area Under ROC Curve (AUC) of the 
full score models for prediction of respective sites.   
Prediction Model AUC SE 
Upper GI cause probability model 0.774306 0.047407 
Lower GI cause probability mode 0.90574 0.045358 
Non-GI cause probability mode 0.821839 0.047375 
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Reduced scoring model 
To create a score that could be easily used, stepwise selection logistic 
regression was used to generate a model with fewer elements to predict site 
of cause of anaemia.  
Table 6.12 demonstrates the results of the selected symptom factors and 
blood indices with respect to each site. 
For upper GI factors, being female and having dysphagia in the presence of 
anaemia were strong predictors. From lower GI factors, age, change in bowel 
habit to loose motions, loss of appetite, and use of NSAIDS were selected. 
For non- GI causes being male, weight loss, warfarin use, chronic disease of 
rheumatoid arthritis and chronic renal failure were selected.  
Hematocrit, MCV and MCH were selected for all sites, haemoglobin and 
serum iron levels were selected for GI causes and MCHC for lower GI and 
systemic causes. RDW was only scored for non-GI cause. 
Using the regression coefficients weights were generated for each factor.  A 
final symptom and blood score was calculated. Both scores were entered in a 
logistic regression model to calculate probability of each site having a 
significant cause of anaemia (Table 6.13, 6.14). 
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Table 6.12: Stepwise regression analysis of symptoms and blood indices with respect to 
site of cause of anaemia. 
Site of cause 
of Anaemia 
Variable 
Regression 
Coefficient 
Standard 
Error 
p value 
Upper GI 
Intercept 0.497252 0.271806 0.067334 
Dysphagia 1.129249 0.833485 0.175465 
Male Sex -0.75341 0.369236 0.041304 
    
Intercept -4.52689 3.803218 0.233936 
MCH 3.602479 1.401863 0.010176 
Male sex -1.66998 0.540062 0.001987 
Hb -0.93545 0.350117 0.007544 
Iron 4.63E-02 3.22E-02 0.150967 
HCT 3.06249 1.108832 0.005746 
MCV -1.12229 0.440005 0.010753 
     
Lower GI 
Intercept -4.4055 1.640754 0.007252 
Age 5.80E-02 2.25E-02 0.010046 
NSAIDS -1.56121 0.521967 0.002781 
Weight loss -1.06482 0.620518 0.086158 
Change in bowel habits to 
loose motions 
-0.68852 0.514419 0.180751 
Loss of appetite 1.546345 0.904979 0.087505 
    
Intercept 79.217 58.34305 0.174534 
Iron 4.15E-02 2.79E-02 0.137544 
MCHC -0.25198 0.192352 0.190189 
Hb 1.522903 0.646263 0.018449 
MCH -3.56346 1.978182 0.071643 
HCT -4.84031 1.99553 0.015284 
MCV 1.119214 0.620663 0.071348 
     
Non GI 
Intercept -1.28112 0.341184 0.000173 
Warfarin -1.2162 0.885015 0.169375 
Male sex 0.96485 0.407127 0.017793 
Weight loss 0.607706 0.449715 0.176595 
RA 2.308212 1.341808 0.085391 
CRF 1.644989 0.928771 0.076537 
    
Intercept -94.8131 46.16448 0.039994 
MCHC 0.318784 0.150913 0.034655 
Male sex 1.456961 0.535447 0.006508 
RDW -0.19852 0.12514 0.112662 
MCH -3.7414 1.819083 0.03971 
HCT -0.12332 8.02E-02 0.124226 
MCV 1.189748 0.572832 0.037805 
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Lower GI probability score had a high discriminatory power but was reduced 
from the full model. In contrast to the full model, upper GI probability score 
had higher discriminatory power than the non-GI cause power (Table 6.15, 
Figures 6.7, 6.8, 6.9). 
 
116 
 
 
1
1
6
 
Table 6.13 Scoring tool  and probability equation for generation of the reduced site 
prediction model.  
 
UGI 
Score 
LGI 
Score 
Non GI 
Score 
AGE 
 
Age x 0.05 
 
Male gender -1 
 
1 
Change in bowel habit 
to loose motion  
-1 
 
Dysphagia 1 
  
Weight loss 
 
-1 1 
Loss of appetite 
 
1.5 
 
NSAIDS 
 
-1.5 
 
Warfarin 
  
-1 
PMH of RA 
  
2 
PMH of CRF 
  
1.5 
Total symptom score 
(SS)    
Male gender -1.5 
 
1.5 
Hb (g/l) X -1 X 1.5 
 
HCT (%) X 3 X -5 X -1.2 
MCV(fl) X -1 X 1 X 1 
MCH(pg)  X 3.5 X -3.5 X -4 
MCHC (g/l) 
 
X -0.25 X 0.3 
RDW 
  
X -0.2 
Iron (μmol/l) X 0.05 X 0.05 
 
Total blood score (BS)    
Y 
-
0.45+(0.99xSS)+(0.32x
BS) 
43+(1.47xSS)+(0.51xB
S) 
0.095+(0.89xSS)-
(0.049xBS) 
Probability for site 
1/[1+Exp(-y)] 
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Table 6.14 Logistic regression of site specific symptom score and blood component 
score with respect site of cause of anaemia.   
Site of cause 
of Anaemia 
Variable 
Regression 
Coefficient 
Standard 
Error 
p value 
Reduced 
Upper GI 
score 
Intercept -0.45308 0.813279 0.577454 
Upper GI symptom score 0.987839 0.445928 0.026743 
Upper GI blood score 0.318355 0.192558 0.098272 
Reduced 
Lower GI 
score 
    Intercept 43.78119 13.47099 0.001154 
Lower GI symptom score 1.474883 0.395772 0.000194 
Lower  GI blood score 0.514304 0.145567 0.000411 
Reduced non 
GI score 
    Intercept 9.50E-02 1.080741 0.929934 
Non-GI symptom score 0.886059 0.260064 0.000657 
Non- GI blood score -4.88E-02 3.62E-02 0.176628 
 
Table 6.15 Discriminatory power assessed by Area Under ROC Curve (AUC) of the 
reduced models for prediction of cause of anaemia at respective sites.   
Prediction Model AUC SE 
Reduced upper GI prediction score 0.721 0.05 
Reduced lower GI prediction score 0.862 0.05 
Reduced non-GI prediction score 0.694 0.05 
 
Figure 6.7: Receiver Operating  Characteristic Curve for the reduced upper GI prediction 
model. 
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Figure 6.8: Receiver Operating  Characteristic Curve for the reduced lower GI prediction 
model 
 
 
Figure 6.9: Receiver Operating  Characteristic Curve for the reduced non- GI prediction 
model. 
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Diagnostic values for the prediction model. 
Average scores of diagnosis groups 
Table 6.16 summarises the average scores of all prediction models and 
patients diagnosis groups. The average scores of both upper GI full model 
and the reduced score were significantly higher in patients who had upper GI 
conditions as the sole cause of anaemia or in combination with colonic or 
systemic disease (Table 6.16, Figure 6.10). 
Lower GI full model and lower GI reduced model also had a significantly 
higher mean scores in patients who had lower GI conditions (ANOVA, 
p<0.01). Furthermore, when there was no significant colonic condition 
causing anaemia the average scores were very low (Figure 6.10). 
Patients with systemic conditions scored significantly high on the non GI 
models.  
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Table 6.16: Average scores of the prediction models and patient diagnosis groups. 
Site of cause of anaemia 
Average prediction scores(Standard Error) 
Full Upper GI 
score 
Reduced Upper 
GI score 
Full Lower GI 
score 
Reduced Lower 
GI score Full Non GI score 
Reduced non GI 
score 
Upper GI disease 71(3) 65(3) 12(3) 17(3) 26(4) 33(2) 
Systemic causes 43(4) 47(3) 15(4) 14(4) 58(4) 45(3) 
Colonic disease 45(7) 49(5) 51(7) 48(6) 34(7) 32(4) 
Upper GI and colonic disease  63(7) 62(6) 64(8) 54(7) 19(8) 31(5) 
Upper GI and systemic disease 48(9) 42(8) 5(10) 5(9) 68(10) 55(7) 
Colonic and systemic disease 50(15) 60(12) 54(16) 41(15) 47(16) 30(11) 
Upper GI, colonic and systemic disease 66(21) 74(17) 50(22) 57(21) 24(23) 18(16) 
ANOVA p values <0.001 <0.001 <0.001 <0.001 <0.001 0.001 
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Figure 6.10: Average scores of prediction models and patient’s diagnosis groups.  
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Patients with upper GI cancers had a higher upper GI full model score than 
other patients although not reaching statistical significance (Table 6.17, 
Figure 6.11). 
 
Table 6.17: Average scores of upper GI prediction models and upper GI cancer 
Group Full Upper GI score Reduced Upper GI score 
Upper GI cancer 73(23) 76(5) 
Others 57(24) 56(19) 
p value 0.16 0.04 
 
 
Figure 6.11: Box plot of full upper GI prediction score and upper GI cancer.  
 
 
The reduced upper GI model however, demonstrated a significant difference 
in average scores between upper GI cancers and other patients (Table 6.17, 
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Figure 6.12: Box plot of reduced upper GI prediction score and upper GI cancer.  
 
There was a significance difference between average scores of lower GI 
cancers and other patients when using both lower GI full prediction and 
reduced prediction models (Table 6.18, Figures 6.13, 6.14). 
. 
Table: 6.18: Average scores of lower GI prediction models and lower GI cancer. 
Group Full Lower GI score Reduced Lower GI score 
Lower GI cancer 53(29) 55(27) 
Others 18(26) 19(22) 
p value 0.0001 0.00003 
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Figure 6.13: Box plot of full lower GI prediction score and lower GI cancer. 
 
 
 
Figure 6.14: Box plot of reduced lower GI prediction score and lower GI cancer.  
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Efficacy of referral guidelines and prediction scores in identification of 
significant causes of anaemia and GI cancer. 
 Thresholds for investigation of the prediction scores were determined using 
the ROC curve with a minimum sensitivity of 80% to the cause of anaemia 
respective to site. For UGI full and reduced prediction model a probability of 
upper GI disease of ≥ 40 was regarded as a threshold for urgent assessment 
of the upper GI tract.  
For lower GI prediction models a probability of ≥15 using the full lower GI 
model and ≥20 using the reduced prediction model was regarded as 
threshold for urgent assessment of the lower GI tract. A systemic cause of 
anaemia was likely when the full non GI model scored ≥23 and the reduced 
non GI model scored ≥ 30.  
Table 6.19 compares the diagnostic values of prediction models, DoH urgent 
referral criteria and BSG threshold of high risk anaemia with regard to causes 
of anaemia and GI cancers.  
Both upper GI prediction models were significant in detecting upper GI 
causes of anaemia at threshold probability of 40. Using these thresholds, 
upper GI causes of anaemia would have been detected in 80% and 85 % of 
patients when the full upper GI model and the reduced models were used 
respectively. DoH and BSG referral criteria did not show a significant 
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prediction of upper GI causes of anaemia with only 32% and 40% 
respectively meeting the criteria. 
The upper GI prediction models had a significantly higher sensitivity to upper 
GI causes of anaemia and referral rates than DoH and BSG criteria (McNemar 
test, p<0.001). There was no significant difference between the two upper GI 
models in sensitivity and referral rates.  
All upper GI cancers (100%) scored above the model score thresholds. 75% 
of the upper GI cancers met the DoH and BSG referral criteria.  This 
difference however, did not reach statistical significance  
The lower GI full model at a threshold score of 15 and the reduced model at 
a score of 20 were both significant predictors of lower GI causes of anaemia. 
DoH criteria were significant in predicting lower GI causes with 55 % of lower 
GI causes meeting the DoH referral criteria. BSG criteria failed to show a 
significant detection of lower GI causes of anaemia. The models were more 
sensitive to lower GI causes than DoH and BSG Criteria (McNemar test, 
p<0.05). All lower GI models had a higher sensitivity to lower GI cancers than 
the DoH and BSG criteria (Table 6.19), however, this was not statistically 
significant (McNemar test, p>0.08) 
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Table 6.19 Efficacy of scoring models and referral criteria and main site of anaemia and GI cancer.    
Cause of anaemia Criteria  Sensitivity Specificity 
Positive 
predictive 
value 
Referral Rate 
UGI causes of anaemia  
Full upper GI model score ≥40 85 55 72 68 
Reduced upper GI model score ≥40 80 44 65 69 
DoH 32 58 48 37 
BSG 40 72 63 34 
UGI cancers 
  
Full upper GI model score ≥40 100 33 5 68 
Reduced upper GI model score ≥40 100 31 4.4 69 
DoH 75 64 7 37 
BSG 75 67 7 34 
Lower GI causes of anaemia 
Full lower GI model score ≥15 91 75 51 39 
Reduced lower GI model score ≥20 87 77 54 38 
DoH 55 69 37 37 
BSG 48 70 35 34 
Lower GI cancer 
Full lower GI model score ≥15 91 68 27 39 
Reduced lower GI model score ≥20 100 70 32 38 
DoH 71 69 26 37 
BSG 71 71 28 34 
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Discussion  
Patients referred for investigation of unexplained anaemia to a dedicated 
clinic had their symptoms and blood profiles collected in a systematic 
manner and analysed.  
Using these symptom profiles and blood indices, an analysis of prediction 
value to the cause of anaemia was performed. This cohort of patients had 
their gastrointestinal tract investigated and a final diagnosis was made in all 
patients after a minimum period of follow up of 1 year.  
The aim of this section was to establish a risk score that predicts the 
likelihood of a cause of anaemia from the upper, lower gastrointestinal tract 
or systemic causes of blood loss. The methodology chosen was multivariate 
analysis using logistic regression to predict individual sites of blood loss using 
site specific symptoms and general blood indices profile. This method has 
been used in clinical prediction models extensively [81, 82, 118-123]. A 
multistep approach was then chosen to adjust for the variation in the degree 
of linearity and slope of correlation between the independent factors and 
the outcome it also reflects the clinical pathway of patients.   
Symptoms and blood indices correlate differently in relation to cause of 
anaemia. This is why it was important to perform two independent 
regression analyses, prediction of site specific symptoms to site of cause of 
anaemia and prediction of blood indices to site of cause of anaemia. 
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Furthermore the data type was binary in the case of symptoms and 
continuous in the case of blood profiles. Hence separating the two would 
allow the regression analysis to handle the variables better. Each generated 
model has thus fitted the respective factors in a relationship that is a linear 
model which transformed the data to a continuous variable. That allowed for 
a better representation of all selected factors, and better regression to 
predict the site of cause of anaemia [117, 124]. 
 Gender has influence within both the symptoms and blood profiles. It is has 
been identified that the incidence of symptoms in the presence of an upper 
or lower GI pathology is significantly different between males and 
females.[74, 108, 111] On the other hand, blood profiles are affected 
differently between genders. Firstly the anaemia threshold is different, 
hence a Hb value of 10 in males is regarded as a significant anaemia but only 
mild in females. This in turn will effect the other indices too (MCV etc.). It is 
more concerning if a male patient presented with symptoms, weight loss and 
haemoglobin of 10 than if a female presents with weight loss and a similar 
haemoglobin value.  
Symptom models: 
The first step of the generation of the model confirmed the poor predictive 
value of symptoms. Both the full model and the stepwise selection model 
(reduced model) failed to identify a strong symptom predictor of site of 
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disease. Traditionally recognised high risk symptoms such as dysphagia, loss 
of appetite and weight loss have demonstrated a tendency to correlate in a 
positive or negative manner with disease sites. This is could be explained by 
the high incidence of non-specific symptoms in this cohort and the rarity of 
clinically significant symptoms such as dysphagia which is a result of rare 
conditions causing anaemia such as oesophageal cancer, or peptic strictures. 
The use of these symptoms in referral guidelines therefore would not aid in 
identifying high risk patients in the majority of cases, and will only yield true 
positives in a few cases. This poor specificity will result in a high referral rate, 
i.e. numbers of patients requiring investigation will be high.  
In our proposed final clinical tool, only dysphagia for upper GI had a positive 
influence on the risk score, for lower GI loss of appetite had a positive 
influence on risk, loose motions and weight loss had a negative influence. 
The negative effect of loose motion in predicting lower GI causes is 
surprising. Loose motions are associated with high incidence of colon cancer 
and IBD[12, 80]. Both conditions cause anaemia. Distal colon cancer however 
is more frequent, does not commonly present with anaemia, and it is 
commonly associated with loose bowel motions [5, 125]. Proximal colon 
cancer on the other hand presents with anaemia and does not have primary 
symptoms except in less than 5% of patients. This would explain the lack of 
positive association with anaemia and loose motions in lower GI conditions 
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causing anaemia identified in this cohort. Only 2 distal colonic cancers, and 2 
IBD patients out of the 31 patients with colonic causes of anaemia where 
identified. The remaining colonic causes do not correlate with loose motions. 
Hence using loose motions with anaemia in classifying patients at high risk of 
significant cause will have a false positive rate. In fact the majority of 
patients with anaemia and colonic causes will have no change in bowel 
habits to loose motions.  
The use of drugs such warfarin and aspirin, the past medical history of 
rheumatoid arthritis, chronic renal failure, and presence of weight loss 
predicted a non-GI cause of anaemia.  
Blood indices model: 
It is important to note that all these patients are anaemic at referral time. It 
is the degree of anaemia that is used to predict the likely cause of blood loss. 
Chapter 3 outlined different patterns of anaemia when cancer was the cause 
it was in the upper GI tract compared with proximal colon cancer. This 
pattern was attributed to the ability of the blood loss from the upper GI tract 
to be reabsorbed in the small bowel, and that overt blood loss from the 
upper GI tract will present with an acute picture rather than chronic loss (i.e. 
mildly low or normal MCV vs. low MCV).  
In this cohort none of the patients presented acutely with blood loss. All 
patients had a slow occult source of blood loss.  
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The final clinical model identified that blood loss from lower GI causes had a 
milder anaemia, but ultimately a defective haemoglobin synthesis due to 
iron depleted erythropoiesis.  This resulted in the low MCH and MCHC as 
reflected by the score. However UGI causes of anaemia had a pattern that 
was opposite to lower GI, with a lower Hb, higher HCT (hemo-concentrated) 
lower MCV, and high MCH.  
The MCV in the multivariate model contributed in a negative manner. The 
MCV in the univariate analysis was lower in lower GI causes as compared to 
upper GI and systemic causes. However when entered in the multivariate 
models this relationship was reversed. This was due to the relative 
contribution of MCV to the total risk in the presence of the other blood 
indices (HCT, MCH and MCHC).   
The profile of blood indices in systemic causes of anaemia is typical of 
anaemia chronic disease, MCV is higher than other causes, MCH is lower, 
and RDW is lower.  
The clinical scoring tool:  
Iron deficiency anaemia could occur due to chronic blood loss from upper or 
lower GI tract or systemic causes. It is also possible that a patient could have 
multiple causes of blood loss [60, 97-103, 105, 126]. In practice when a 
patient is referred for investigation of unexplained anaemia, once history 
and physical examination are obtained, an upper or lower GI tract 
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investigation or both is performed. Traditionally blood indices have no role in 
this decision.  
This study combined both symptoms score and blood score to generate a 
risk score predicting the likelihood of anaemia caused by an upper, lower GI 
tract or systemic cause.  
Two types of scoring tools where generated, a full model that incorporated 
all symptoms and blood indices and a reduced model by selecting influential 
factors only. Due to the large number of variables, rarity of some symptoms 
the error margin of the full model will be high. Although it had a high 
discriminatory power as confirmed by the area under the Receiver Operator 
Characteristic curve compared with the reduced model it would be difficult 
to apply in clinical practice. The reduced model selected fewer factors and it 
will be easier to apply in clinical practice.   
The clinical tool (table 6.13) generates three scores (upper GI, lower GI, and 
systemic score). Each score reflects the risk of anaemia caused by the 
respective site. It is clear from table 6.16 that the scores were higher when a 
respective site was identified as a cause of anaemia. Even when patients had 
more than one site contributing to the anaemia the score of that respective 
site was higher than other scores. Patients who had an upper GI cause for 
their anaemia had an average score of 65 in the reduced model compared 
with a score of 17 for lower GI tract and 33 for a systemic cause. Patients 
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who had upper and colonic cause of anaemia had both respective average 
scores higher than systemic causes (mean reduced model scores of upper GI 
score 62, lower GI 54, systemic 31) (table 6.16, figure 6.10).  Patients with GI 
cancers at the respective sites also had high respective scores.  
As the score was a continuous scale a cut-off point needed to be determined 
to classify patients into high and lower risk groups. By doing so if a patient 
scored higher than the cut-off, it indicated investigation of that site as a 
matter of priority. This cut-off had to achieve a minimum of 80% sensitivity, 
i.e. 80% of the population with respective group pathology have to score 
above the chosen threshold of the respective risk score. The performance of 
the risk scores was compared to current guidelines. The UGI risk scores 
identified > 80% of patients with UGI causes of anaemia. In contrast < 40% of 
these patients met the DoH and BSG guidelines of urgent referral. However, 
the risk scores resulted in a significant increase in the number of patients 
needing to be investigated. All UGI cancer patients scored high on the UGI 
score and only 75% met the DoH and BSG guideline. This was reproduced for 
lower GI pathology and cancers, except for a lower and similar referral rate 
between the scores and guidelines.   
The scores had a better performance in detecting UGI causes due to the 
ability to take into account the haemoglobin value at all levels below normal 
in contrast the DoH 11g/dl for men and 10g/dl for women thresholds. It also 
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performed better than the BSG guidelines due to the ability to take into 
consideration the different levels of MCV and other blood indices effect on 
risk. The resultant increase in referral is explained by the fact that majority of 
referred population had an UGI cause of anaemia and that upper GI causes 
had presented with higher MCV and milder anaemia.   
In the case of lower GI causes and cancers, although the guidelines had a 
reasonable sensitivity (majority of patients had a low MCV and lower Hb), 
they had lower specificity. The scores identified more patients with 
pathology than the guidelines without increasing the referral rate. This 
higher specificity and sensitivity is due to accounting for the effect of blood 
indices and symptoms in prediction of site of blood loss. (Table 6.9 and 6.14) 
In summary incorporating presenting symptoms and blood indices at time of 
referral generated a risk score predicting the likely site of blood loss. The 
scoring tool is able to differentiate patients with multiple causes of blood 
loss. Current guidelines will identify 75% of upper GI cancers, and 71% of 
lower GI cancers, but will miss more than 45 % of other causes of anaemia. 
The scoring tool will identify more patients with cancers and other pathology 
causing anaemia as high risk than current guidelines.  
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Chapter 7 
Discussion and Conclusion 
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Colorectal and upper GI cancers are among the leading causes of cancer 
related death in the UK. Survival in the UK is yet to improve to come into line 
with survival from cancer in Europe. In addition to screening, the DoH has 
focused on improving the journey of patients at high risk of having cancer 
from referral to diagnosis, in an attempt to detect cancer at an early stage. 
The effectiveness of improving cancer survival has been achieved in 
colorectal cancer by mode of screening [127-129]. However, no advantage 
has been identified by introducing screening for upper GI cancer in the UK, 
which increases the emphasis for a need to improve detection of upper GI 
cancer in symptomatic patients.  
IDA is a common denominator for high risk criteria for urgent referral of 
colorectal cancer and upper GI cancer. In 2000 the BSG introduced its 
guidance on investigating patients with IDA, which aim to streamline 
patient’s investigations and ensure that the upper and lower GI tract are 
examined.  
This thesis aimed to identify profiles of blood indices and symptoms that 
could aid in development of a streamlining scoring tool to aid investigation 
of anaemic patients.  
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Blood indices patterns of cancer 
GI malignancies can present with anaemia secondary to overt or occult blood 
in the GI tract. This study investigated the blood indices profile in a 
consecutive cohort of common GI malignancies and a cohort from primary 
care.  
Focused analysis of the anaemic profiles of oesophageal, gastric and 
proximal colon cancers (PCC) was undertaken. These cancers are 
representative of sites of the GI tract that commonly present with anaemia. 
Patients with distal cancer were not included in this study as they do not 
commonly present with anaemia [11, 90]. However when distal colonic 
cancer does presents with anaemia it is similar to PCC in profile[90].    
In this cohort a significant number of PCC and gastric cancers are anaemic at 
presentation (PCC 75%, gastric cancers 67%). In contrast less than a third of 
oesophageal cancers (27%) presented with anaemia.   
Sub analysis of anaemic cancer patients demonstrated a significant 
difference in anaemia profile of cancer groups. PCC had a lower MCV, MCH, 
MCHC and a higher RDW than upper GI cancers.  These profiles are indicative 
of iron deficient state[48, 92].  PCC when compared to distal cancers 
commonly presents with IDA [11, 12, 90, 130, 131]. The profile of blood 
indices of colorectal cancers was studied in detail by Sadahiro et al. [90]. 
They demonstrated a tendency for PCC at later stages of cancer and larger 
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tumours to present with lower Hb and lower iron levels. No study has looked 
at the difference in the profile of blood indices between upper and lower GI 
tract in depth. The difference in the MCV, MCH, MCHC and RDW between 
upper and lower GI cancers is attributed to the level of iron deficiency. 
Studies that measured blood loss from the GI tract demonstrated a tendency 
of colonic causes to have detachable blood loss in whole gut lavage [93, 94]. 
It was found that in patients who had an obvious condition in the upper GI 
tract that is commonly seen in patients presenting with IDA, whole gut 
lavage was negative[93]. The investigators suggested that the blood loss 
from these lesions is either intermittent or the pathologies were 
coincidental. The former is likely as anaemia resolves once the conditions are 
treated. High bioavailability of heme iron [92] could explain the slower 
progression of upper GI blood loss to IDA, as a high proportion of lost iron 
from the GI tract is reabsorbed in the duodenum.  
RDW is a reliable early index to detect IDA[132].  It has a high sensitivity and 
specificity for PCC [89]. In our cohort RDW had a tendency to increase with 
PCC as compared to upper GI cancers. The value of RDW is higher when Hb is 
normal [89], as it detects iron deficient state before anaemia ensues. This is 
represented in our data with the higher RDW in PCC compared with upper GI 
cancers, which reinforces the earlier onset of iron deficiency in PCC than on 
upper GI cancer.  
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Chronic blood loss from the GI tract results in a gradual depletion of iron 
stores, which will eventually result in anaemia.  This process has phases.  
Reduction in size and haemoglobin content of RBCs occurs in iron deficient 
erythropoiesis before anaemia occurs. This early phase of iron deficiency will 
produce different populations of red blood cells, which is seen in blood films 
as poikilocytosis and that could be measured in FBC analysis as a high RDW.  
Cancer has two phases, an asymptomatic and a symptomatic phase. Along 
the same time line tumours continue to grow causing an advancement of 
stage and increase in GI blood loss. Using symptoms to detect cancer 
successfully at an early stage relies on an overlap period of early stage of 
cancer with early symptom phase (Figure 7.1). The longer this period is the 
higher the success rate of cancer detection, provided that the patients and 
health professionals have high awareness and vigilance.  
In the GI tract where luminal space is relatively small (oesophagus, distal 
colon), the growth of a tumour will result in the presence of symptoms 
earlier compared with more capacious viscera (stomach, proximal colon). 
This explains the higher predictability of distal colonic symptoms for distal 
colon cancer and dysphagia for oesophagus. Hence blood loss from cancers 
in the proximal colon and stomach gains more relevance as symptoms, when 
they emerge, will be related to a later stage of cancer (Figure 7.1).   
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Figure 7.1: Evolution of symptoms, stage of cancer and anaemia. 
 
 
 
The DoH and BSG referral guidelines anaemia thresholds were met in only 
22% and 25% of the GI cancer cohort respectively. PCC had a higher 
proportion of cancers meeting the DoH and BSG referral thresholds (39%, 
49% respectively) compared with gastric (16%, 19% respectively) and 
oesophageal cancers (7%, 7% respectively). Due to the higher threshold of 
referral of DoH and BSG referral guidelines, a drop from of 57% detection 
rate for GI cancers to 22% and 25% respectively was observed.  By lowering 
the referral thresholds to include any patients with unexplained anaemia 
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regardless of MCV needing urgent assessment, a significantly higher 
proportion of cancers will be identified. However this is will increase the 
demand.  
The first recommendation of this thesis thus is to lower the threshold of 
referral to achieve a higher sensitivity for cancer detection. But to improve 
specificity a further adjunct to that criterion is needed.   
Symptoms of GI conditions and the identified different profiles of anaemia of 
GI cancers (Low MCV MCH, MCHC, higher RDW in PCC  compared with upper 
GI cancer) provides a potential for a differentiating tool to aid in identifying 
patients who have significant GI causes of anaemia.  
 
Diagnosis, symptoms and blood profiles of cohort investigated for 
unexplained of anaemia.  
In the second stage of this research a cohort of patients with unexplained 
anaemia underwent an upper and lower GI investigation for causes of 
anaemia with a cause established in 95% of patients. 6 patients had iron 
deficiency responding to iron and resolved completely with no further 
pathology identified at one year follow up. High compliance with invasive 
investigations was observed, although compliance with FOB testing was 
poor.  
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This study confirmed that upper GI causes of occult blood loss were the 
commonest (40%), followed by systemic (30%) and lower GI causes (14%). 
Cancer incidence was highest in the lower GI tract with 65% of the patients 
with a lower GI cause of anaemia having colon cancer followed by patients 
who had dual upper and lower GI patients with 55% having colon cancer in 
addition to a benign upper GI cause of anaemia.  
It was evident that compliance with national guidelines was poor as many 
patients with alarm symptoms and anaemia were not referred urgently. 
However 28% of dyspeptic patients who had anaemia were referred urgently 
and only 22% of patient with dysphagia were referred urgently.  
 
The commonest upper GI symptoms of heart burn and dyspepsia had an 
associated significant cause of anaemia in 48% and 50% of patients 
respectively.  
The incidence of heart burn and reflux has been reported to be 10% to 48% 
in the general population [30].  Dysphagia was reported in 9(7%) of the 
studied cohort. None of the upper GI symptoms had a significant difference 
in their distribution with respect to cause of anaemia, type of cancer or route 
of referral. 
Dyspepsia is non specific to organic conditions of the upper GI tract[107]. 
However, when detailed scoring of symptom has been performed, it was 
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able to identify patients at high risk of having significant pathology in the 
upper GI tract[108].  
The yield of cancer diagnosis from symptom referrals for patients with alarm 
symptoms of upper GI tract has been low, with incidence ranging from 4% to 
15% [74, 109].  
The value of these symptoms in our anaemic patients was not confirmed in 
univariate or multivariate analysis. However when mutually exclusive 
symptoms were removed by stepwise regression analysis, dysphagia 
approached significance in male patients. It was thus selected in the 
streamlining tool. 
 Previous studies have included high risk symptoms such as dysphagia and 
weight loss as individual factors or in scoring systems to identify significant 
upper GI disease and cancer with success, with an odds ratios of 2 for upper 
GI disease and 6 for cancer [31, 74, 110].  
Change in bowel habit to loose motion or alternating loose motion and 
constipation was the commonest lower GI symptom reported. None of the 
lower GI symptoms had a significant relationship with a site of cause of 
anaemia except for constipation which was higher in patients with upper GI 
cancer (22%).  
Loose motion and blood in the stool in the absence of perianal symptoms are 
high risk factor for significant lower GI disease with high predictive value for 
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cancer, colitis and large polyps [18, 27, 111, 112]. However their association 
with PCC is poor. Loose motion has been included in a risk score by Fijten et 
al to predict colorectal cancer [12]. However Majumdar et al demonstrated 
1.96 odds ratio of distal cancer when cluster symptoms (included loose 
motions) existed [11]. Even in the presence of anaemia loose motions does 
not help predict PCC.  
Stepwise regression analysis of lower GI symptoms demonstrated a reverse 
trend relationship between loose motions and significant lower GI 
pathology. This is explained by the fact that only 26 % of the cohort had a 
colonic condition that is commonly associated with loose motion. Loose 
motion was also prevalent in patients with upper GI disease (58%) and the 
majority of anaemic patients had upper GI disease. The above two reason 
rendered loose motion less specific to colonic conditions. This explains the 
reverse relationship.      
Weight loss was reported in 32 (25%). The majority of these patients had a 
significant upper GI cause of anaemia. Only 19% of the cancer patients 
reported weight loss.  
Blood profiles showed patterns that were correlating with causes of 
anaemia, with cancer patients having significantly lower haemoglobin and 
other blood indices compared with the non-cancer patients. Upper GI causes 
had a tendency to have a higher MCV, MCH and lower RDW compared with  
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lower GI causes. This is explained by the longer silent phase of lower GI 
cancers and the potential of re absorption of heme from the upper GI tract 
slowing the progression of iron deficiency.   
Iron studies, as well as B12 and folate, did not show significant differences 
between site causes of anaemia. However, cancer patients did show a low 
ferritin level compared with non-cancer patients. This was even more 
pronounced in colonic cancers compared with upper GI cancers.  
Results of logistic regression and stepwise regression analysis demonstrated 
a pattern of blood profiles that correspond to site of cause of anaemia. 
Systemic causes of anaemia had a higher MCV, and MCHC with a lower RDW, 
MCH, and HCT.  This reflects the common mechanism of non-GI causes of 
anaemia in this population [49, 113, 114]. Erythropoiesis is deprived of iron 
as it is sequestrated in chronic inflammation response[49]. It is common that 
these patients present with normocytic (normal MCV), normochromic 
(normal MCHC)[48, 115].  
The relatively normal RDW is likely due the slow development of anaemia in 
this patients and chronicity of the condition which results in a homogenous 
population[116]. As there is anaemia, the HCT and MCH decrease.  
When assessing the pattern from GI causes of anaemia; it is evident that 
there is a pattern differentiating upper vs. lower GI causes.  
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In univariate analysis colonic causes of anaemia had a lower MCV, MCH, 
MCHC and a higher RDW compared with upper GI causes. This is similar to 
the demonstrated pattern in this study of GI cancer anaemic profiles. The 
regression analysis confirms the trend of higher MCH, HCT and higher serum 
iron in upper GI causes, and lower MCHC, MCH and HCT in lower GI causes.  
The regression models using blood indices demonstrated a good 
discriminatory power to sites of cause of anaemia independently and in 
combination with symptoms. 
A prediction model was designed using the interaction between symptoms 
and the identified trends of blood indices with the site of cause of anaemia.   
Both the symptom based scoring models were effective in discriminating 
lower GI causes of anaemia (AUC 0.86) better than models for upper GI(AUC 
0.72) and systemic causes(AUC 0.69).  
Patients with upper GI cancer scored high on upper GI prediction model 
compared with other patients. Likewise, lower GI cancer scored high on the 
lower GI scoring tool compared with other patients.  
The streamlining tool in clinical setting 
Two prediction models were calculated for each site, a full symptom and 
blood comprehensive model and a reduced model. In order to allow for 
better implementation of the scoring tool in a clinical setting a simple and 
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practicable tool is needed. The full model involves entering all factors in a 
large complicated equation. Hence it was not suitable for clinical settings. 
Stepwise regression analysis provided a systematic approach in selecting 
factors for the reduced model. 
The reduced model had a higher sensitivity and specificity to detecting 
causes of anaemia compared with the current guidelines. It was also 
effective in predicting the site of cause of anaemia. Although the models had 
a higher sensitivity to cancer compared with the guidelines this did not reach 
statistical significance.  
Recently there has been a rise in the use of scoring modalities in clinical 
settings. Such scoring modalities could provide a risk estimation for surgery 
as is in the POSSUM score [81, 119], mortality risk of critically ill patients as 
in APACHE II[122, 123, 133], prioritisation of  patients based on severity of  
symptoms as is in the Oxford Hip Score [134-137], or risk of cancer based on 
colorectal symptoms like that achieved by the Selva score[111]. The success 
of these models is dependent on the efficacy of the score and their 
practicality and ease of use.  
A scoring tool that would help streamline and identify patients at risk of 
having a significant cause of anaemia has been developed. It can be used in 
conjunction with current BSG guidance to help identify patients who have 
dual pathology and hence would need a bidirectional endoscopy (figure7.2). 
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Figure 7.2: Proposed clinical pathway for streamlining investigation of 
patients with anaemia 
 
 
55% of patients who had dual pathologies of both upper GI and colonic 
causes of anaemia had colon cancer as the lower GI cause. Had the BSG 
guidelines been adhered to, then an OGD would have been organised. As a 
result of that, a significant upper GI pathology would have been identified 
and ultimately identification of the colon cancer would have been dependant 
on anaemia not resolving after trial of treatment or development of 
symptoms pertaining to the lower GI tract.  Both possibilities would result in 
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delay in diagnosis and potentially result in advancing the stage of cancer.  
The scoring tool would identify these patients requiring bidirectional 
endoscopy and eradicate delay in detecting the colon cancers.  
The current referral guidelines for suspected cancer have not as yet achieved 
an improvement in stage of upper or lower GI cancers detected. There has 
been however a reduction in emergency admission rates in colorectal 
cancers [138]. This success is multi factorial, but there is evidence that the 
reduction in delays in diagnosis of symptomatic colorectal cancers is 
contributing to this. Improvement in upper GI cancers emergency admission 
is yet to be demonstrated.  
In this study only 4 upper GI cancers were identified. Hence it would require 
a larger study to assess the effect of the tool on the stage of upper GI cancer.  
Prior to the introduction of referral guidelines none of the PCC presented 
with anaemia and early stage of cancer at our hospital (table 7.1).  
There was a significant delay in completing colonic investigation following 
upper GI investigation (Chapter 1, Table 1.5). Furthermore, haemoglobin had 
to drop below 100 g/l in females and 110 g/l in males before an urgent 
investigation was triggered. 
In this cohort, 23% of PCC were Duke’s A stage. This stage migration was 
statistically significant (chi-square, p=0.02) and achieved a post hoc power of 
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76%.  This indicates a potential of the implemented protocol to improve 
stage of cancer at diagnosis.  
 
Table 7.1: Duke stage of anaemic proximal colon across two reference periods.   
 
Dukes Stage 
PCC in Cohort(2003-
2004) 
Anaemic PCC between 1998-2001 
A 3(23%) 0 
B 3(23%) 17(44%) 
C 5(39%) 15(38%) 
D 2(15%) 7(18%) 
 
Lowering the threshold of anaemia to trigger an urgent referral earlier and 
use of the scoring tool would help identify patients at risk of having a serious 
cause of anaemia in the GI tract. It will also help identify patients with 
potential significant dual pathologies. 
In this study a dedicated anaemia clinic provided rapid assessment of 
patients referred with unexplained IDA. It has a structured interview format 
with a standardised investigation protocol. The clinic was doctor led, 
however it has the potential to be run by a nurse practitioner trained to 
apply the protocol. At the end of the study period the accompanying nurse 
practitioner was capable of applying the pathway safely and effectively.    
It is proposed that the patient is interviewed using the structured scoring 
tool and blood profile results are obtained (table 6.13). He or she could be 
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directed to the investigation pathway of the score that is above the 
threshold (figure7.2). If a diagnosis is not established then reassessment of 
the GI tract needs to be considered and perhaps repeat GI investigations 
with a different modality.  
Patients who score high on the systemic score and below the threshold in 
the other two scores should have the investigation of the highest GI score 
(figure 7.2). If that is clear then complete the loop of GI investigation.  
However on validation of the tool on a larger population, should the 
systemic score be so sensitive and specific, patient with low GI scores and 
high systemic score could avoid an un-necessary investigation. 
One of the limitations of this study is a lack of complete assessment of the 
small bowel in all patients.  Particularly in patients labelled as having 
systemic disease. Although requested, small bowel assessment was not 
completed except in patients who had high suspicion of small bowel 
pathology. Interestingly, after a 1 year follow up none of the patient 
developed small bowel pathology. This however does not exclude the 
potential of missing celiac disease, or small bowel disease.  
Celiac disease was diagnosed in 7 studies out of the 18 reviewed (chapter 1). 
The incidence ranged from 2% to 11% (table 1.9). In 2 studies other small 
bowel pathologies were identified [100, 102].  
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The proposed streamlining pathway in addition to its compliance with 
recommended BSG guidelines, would also achieve a diagnosis of site specific 
pathology more rapidly as the loop is started with the highest yield test. It 
also allows for quantifying the risk of dual pathology allowing for direct 
booking of patients to bidirectional endoscopy, which in turn saves times 
and resources.     
Conclusion  
A scoring tool has been developed which could be applied in the clinic or 
incorporated into computer-based decision support software.  
Validation of the tools accuracy and efficacy and further refinement is 
essential on a larger population.  
IT is recognised however that there are limitations in the studies which have 
been conducted.  
There are multiple factors that have been evaluated and the current sample 
size and the high number of symptoms does not allow for reliable statistical 
analysis. This work has been used as a pilot study to identify potential factors 
that could aid in the development of the scoring tool and set the foundation 
for a validation study. 
Small bowel investigation was selective, So there is a risk of missing small 
bowel disease.  That is also a risk with current guidelines for conditions other 
than coeliac disease.   
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We propose validation of the tool on a larger cohort. The primary outcome is 
to validate the accuracy of the scoring tool to achieve a correct diagnosis in 
90% of the patients. That cohort can be used to further refine the score and 
investigate the utility of adding further symptoms to the score.  
A nurse led clinic could also be explored and feasibility and safety could be 
confirmed.  
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Appendix 1: Literature review of studies investigation patients with iron deficiency anaemia 
 
Reference 
N Upper GI Colorectal Cause Dual Non GI  Note 
Annibale et al[57] 71(85%) Gastric Cancer  2 
Peptic ulcers 7 
Hiatus Hernia with 
erosion 5 
Atrophic gastritis 19 
 Celiac 4 
H pylori 13  
Colon Cancer 10 
Vascular Ectasia 3 
Polyps 2 
Crohn’s 1 
 
8%  Non bleeding 
causes seen in 
younger patients 
Gordon et al [66] 170 70(41%) 
Peptic ulcer 15% 
Oesophagitis 8% 
Gastritis 75 
Gastrectomy 6% 
Celiac disease 3% 
 
30(18%) 
Colon cancer 9% 
UC 4% 
AVM 3% 
 70(41%)  
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Cook et al[39] 100 60(60%) 
Oesophagitis 14 
Erosions 14 
Ulcer 8 
Oesophageal cancer 1 
Gastric cancer 5 
HH > 10cm 7 
Varices 3 
Angiodysplasia 5 
Gastric surgery 10 
 
23(23%) 
Cancer 14 
Polyps 6 
Vascular ectasia2 
Ulcerative Colitis 1 
Crohn’s 2 
 
 12(14%) 
 
 
Rockey et al[64] 100 37(37%) 
Ulcer 19 
Oesophagitis 6 
Gastritis 6 
Vascular ectasia 3 
26 (26%) 
Prox Colon Cancer 8 
Distal Colon Cancer 3 
Angiodysplasia 5 
IBD 2 
1% 38%  
 
178 
 
 
1
7
8
 
Gastric cancer 1 
Polyp 1 
Portal hypertensive 
gastropathy 1 
 
Caecal ulcer 2 
Polyp 5 
Parasitic infestation 1 
Zuckerman et al[40] 100 36(36%) 
Oesophagitis 6 
Gastric Ulcer 6 
Erosion 12 
Duodenal Ulcers 1 
Duodenal erosioin2 
Vascular ectasia 8 
Varices 2 
Polyp 1 
Gastric cancer 1 
26(26%) 
Polyps 14 
Colon cancer 6 
Vascular ectasia  5 
Ulcers 2 
 
9(9%) 47(47%)  
McIntyre et al [37] 111 45(39%) 
Gastric ulcer 13 
18(16%) 
Polyp 8 
10(9%) 31% OGD flexi and 
barium enema  
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Duodenal ulcer 10 
Gastric cancer 8 
Oesophagitis 15 
Erosive Gastritis 7 
Celiac disease 3 
Gastrectomy 2 
Other ? NSAID 2 
Prox colon cancer 4 
Distal colon cancer 1 
Ulcerative Colitis 2 
Vascular ectasia 1  
Other 3 
 
Only 93 patients 
completed full 
upper and lower GI 
investigation.  
Hardwick et al[41] 89 53(60%) 
Oesophagitis 26 
Barrett’s ulcer 1 
Oesophageal cancer 2 
Gastric Cancer 7 
Peptic Ulcer 10 
Lymphoma 2 
Celiac disease 2 
Jejunal cancer2 
Ampullary cancer 1 
50(58%) 
Prox colon cancer 26 
Distal colon cancer 7 
IBD 9 
Colonic polyps 8 
Angiodysplasia 2 
Ileal carcinoid 1 
 
 
 
26(29%) 9  
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Kepczyk et al [65] 70 39(56%) 
Gastric Erosions 11 
Oesophagitis 10 
Watermelon stomach 
4 
Celiac 4 
Gastric Ca 3 
Gastric Ulcer 3 
Duodenal Ulcer 3 
Polyps 2 
Lymphoma 1 
Oesophageal cancer 1 
Crohn’s disease 1 
21(30%) 
Prox colon cancer 2 
 Distal colon cancer 2 
Polyp 7 
Vascular ectasia 6 
Haemorrhoids 4 
IBD 1 
 
12(17%) 5 (7%)normal Piles 60ml a day 
>3/weeks fro 6 
month 
Landy et al[59] 478 63(13.2%) 
Cancer 10 
Oesophagitis 4 
Stricture 1 
62(13%) 
Cancer 24 
Polyp 18 
Vascular ectasia 11 
7(1.5%)  Retrospective 
analysis of 
prospective 
collected data.  
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Barrets 20 
Ulcers 17 
Vascular ectasia 12 
IBD 9 
 
Only reported 
predefined causes 
of IDA. Gastritis, 
duodenitis was not 
reported even if it 
was the only 
finding  
Nahon et al [60] 117 54(46%) 
Gastritis 17 
Oesophagitis 9 
Cancer 7 
PUD 9 
Gastric polyp 6 
Vascular ectasia 3 
 
31(26.5%) 
Cancer 14 
Polyp 10 
Vascular ectasia 5 
4%  Women only.  
Urquhart et al[61]  6538 2184(33%) 
Cancer 22 
1505(23%) 
Cancer 116 
  Retrospective 
analysis of 
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Vascular ectasia 231 
Ulcers 377 
Barret’s 252 
Stricture 241 
Vascular ectasia 251 
Polyp 409 
prospectively 
collected data. 
20.9% of the 
population was 
under 50years old 
only 5%<40 
Other findings not 
listed(16% upper GI 
, 11% lower GI) 
Capurso et al [78] 98 20(20%) 
Ulcer 9 
Hiatus hernia with 
Cameron ulcers 7 
Gastric Cancer 5 
Atrophic gastritis 14 
H pylori 15 
Coeliac disease 11 
27(27.5%) 
Colon cancer 13 
Polyp 4 
Vascular ectasia 4 
Severe Diverticular 
disease with FOB+ 5 
IBD 1 
8(8%)   
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Gastric surgery 5 
Park et al[104] 749 Oesophagitis 1 
Gastritis 16 
Peptic Ulcers 71 
Polyp 1 
Gastric cancer 14 
 
Colon cancer 25 
Piles 25 
Tuberculosis 8 
IBD 9 
Vascular ectasia 3 
Polyp 21 
 
   
Bampton et al [99] 80 Oesophagitis 14 
Peptic Ulcers 8 
Gastric Polyp 4 
Gastritis 2 
Portal hypertensive 
gastropathy 2 
Gastric cancer 1 
Vascular ectasia 1 
Duodenal polyp 2 
Colon cancer 7 
Polyps 5 
Colitis 1 
Vascular ectasia 1 
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Hiatus hernia >10cm 2 
Post-Gastrectomy 3 
Joosten et al [63] 96 Oesophagitis 12 
Gastritis 17 
Gastric ulcer 5 
Duodenal ulcer 7 
Vascular ectasia 6 
Polyp 4 
Gastric cancer 2 
 
Polyp 10 
Vascular ectasia 6 
Colitis 1 
Colonic cancer 13 
Piles 1 
  Elderly >70years 
old  
Sari [103] 95 Gastritis 16 
Duodenal ulcers 15 
Gastric ulcers 8 
Gastric cancer 7 
 Celiac disease 2 
Oesophagitis 7  
Colon cancer 5 
Piles 3 
Polyps 1 
Colitis 1 
 Normal 30 Age > 50years 
Coban[76] 96 Duodenal ulcer 14 Colon cancer 8 I dual pathology   
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 Gastritis 12 
Oesophagitis 11 
Gastric ulcer 11 
Gastric cancer 6 
Polyp 3 
Oesophageal cancer 1 
Piles 6 
Polyp 3 
Diverticular disease 3 
Vascular ectasia 2 
Colitis 2 
Niv et al[102] 48 Oesophagitis 2 
Hiatus hernia with 
erosions 2 
Gastritis 9 
Duodenitis 1 
Duodenal ulcer 1 
Gastric cancer 2 
Small bowel cancer 1 
Polyps 3 
Colon cancer 11 
Vascular ectasia 3 
3 dual pathology   
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Appendix 2: Anaemia symptom proforma
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Appendix 3: Multistep approach in development of the full 
scoring tool.  
 
  
  
site specific  
symptoms 
and constitutional 
symptoms 
Full Upper GI 
symptom score 
Full lower GI 
symptom score 
Full Non GI 
symptom score 
Blood profile indices 
Full Upper GI blood 
score 
Full lower GI blood 
score 
Full Non GI blood 
Score  
Full Upper GI 
combined score 
Full lower GI 
combined score 
Full Non GI 
combined score 
Logistic 
regression 
Logistic 
regression 
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Appendix 4: Multistep approach in development of the reduced 
scoring tool.  
 
 
 
 
 
 
site specific  
symptoms 
and constitutional 
symptoms 
Reduced upper GI 
symptom score 
Reduced lower GI 
symptom score 
Reduced Non GI 
symptom score 
Blood profile indices 
Reduced Upper GI 
blood score 
Reduced lower GI 
blood score 
Reduced non GI 
blood Score  
Reduced Upper 
GI combined 
score 
Reduced lower 
GI combined 
score 
Reduced Non GI 
combined score 
Stepwise 
Logistic 
regression 
Logistic 
regression 
